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I.1. The liver 
The liver is the largest organ of the human body, and is located in the upper 
right corner of the abdomen (Figure I.1.A) [1]. It performs multiple metabolic and 
homeostatic functions such as: a) synthesis and storage of glycogen, fat and fat 
soluble vitamins, b) synthesis and release of different products such as glucose, 
plasma proteins, clotting factors, urea, c) bile production, as well as d) drugs 
detoxification, among others [2, 3]. The liver is composed by different cell types 
(Figure I.1.B): i) parenchymal cells or hepatocytes, ii) sinusoidal fenestrated 
endothelial cells, iii) perisinusoidal stellate cells, iv) intraluminal phagocytic 
kupffer cells, and v) biliary duct epithelial cells. These cells interact with each 
other executing specific functions. The main cell type in the liver is the 
hepatocyte, which represents ~80% of the total volume and performs most of 
the liver functions [3]. 
The liver has a unique vascular system and its blood supply is divided 
between the hepatic artery (~25-30%) and the portal vein (~70-75%). The 
hepatic artery provides oxygenized blood to the liver and the portal vein carries 
a nutrient-enriched blood from the small intestine [4]. Both types of blood, 
arterial and portal, end up mixing within the hepatic sinusoids before draining 
into the systemic circulation through the hepatic venous system, for example 
the central vein (Figure I.1.B) and the inferior cava vein [4]. Following the portal 
venous system trajectory it is distinguishable the intrahepatic biliary tree (Figure 
I.1.B) [4], composed by bile epithelial cells (termed cholangiocytes) that 
participate in the regulation of bile composition.  
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A) B) 
Figure I.1. A) Anatomical localization of the liver in a human body (http://es.123rf.com). 
B) Liver cell types, and blood and bile flow in the liver (modified from Gordillo M et al,
2015, Development) [5]. 
I.2. Biliary tract 
I.2.1. Anatomy 
The biliary tree is a network of interconnected ducts of increasing diameter from 
the liver to the intestine, which can be subdivided into intrahepatic bile ducts 
(IHBDs) and extrahepatic bile ducts (EHBDs) [6]. IHBDs start at the ductule-
canalicular junction with the canals of Hering (Figure I.1.B), which are located at 
the periphery of the portal tracts facing the periportal hepatocytes [7]. IHBDs 
continue with the bile ductules and the interlobular septal area and segmental 
ducts [6]. EHBDs consist of right and left hepatic ducts, common hepatic duct, 
gallbladder with the cystic duct, common bile duct, and hepato-pancreatic 
ampulla. The resultant bile drains into the duodenum (Figure I.2) through the 
papilla of Vater [6]. The right and left hepatic ducts and the proximal portion of 
the EHBDs are collectively called “perihilar bile ducts” [8]. 
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Figure I.2. Anatomy of the extrahepatic biliary system (modified from 
http://www.myschoollights.com/human-liver.html). 
 
I.2.2. Bile duct epithelial cells: cholangiocytes 
The bile ducts are lined by specialized epithelial cells called “cholangiocytes”. 
Cholangiocytes, which represent ~3-5% of total liver cells, play key roles in the 
regulation of bile flow and composition. They are involved in the fluidization and 
alkalinization of the primary bile generated in the canaliculus of hepatocytes [9], 
and may participate in the reabsorption of bile acids [10]. 
Cholangiocytes are characterized by the presence of a single primary cilium 
that extends from the apical membrane into the bile duct lumen (Figure I.3) [11]. 
This antenna-like bulge is a sensory organelle that functions as a mechano-[12], 
chemo- [13] and osmo-sensory organelle [13, 14], which detects changes in bile 
flow, composition and osmolarity and has an important role in cholangiocyte 
physiology and pathophysiology [11, 12]. It is formed by an axoneme and a 
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centriole-derived basal body [11]. The axoneme is composed by 9 duplets of 
acetylated alpha-tubulin located in the peripheria of the cilium, indicating its 
main sensory function and no duplets in the center, indicating the lack of 
capacity to move the fluids [11]. 
 
Figure I.3. The normal structure of a cholangiocyte primary cilium composed by a basal 
body and an axoneme, and cross- ciliary section of the primary cilium showing  9 
duplets of acetylated alpha-tubulin in the peripheria (modified from Masyuk TV et al, 
The American Journal of Pathology, 2004) [15].  
 
I.2.3. Embryogenesis and development  
I.2.3.1. Gestational stages and biliary system embryogenesis 
In mammalian embryos, the hepatobiliary system derives from the ventral 
foregut endoderm [16]. In humans, in particular, the first formation of bile ducts 
and liver is the hepatic diverticulum, which starts as a thickening of the 
endoblastic epithelium of the foregut endoderm at the 18-day of gestation [17]. 
In the 22-day of gestation the hepatic diverticulum is well formed (Figure I.4) 
[17]. In the development of the human biliary system, the EHBDs develop from 
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the embryonic hepatic diverticulum whereas the IHBDs originate within the liver 
from the ductal plate [18, 19]. 
Figure I.4. Liver diverticulum and bud formation in mouse. HE: hepatic endoderm; ST: 
septum transversum; EC: endothelial cells [5]. 
 
During the 29-34 days of gestation, the embryo (~5 mm in length) shows in 
the hepatic diverticulum a protruding bud that represents the initial formation of 
the gallbladder, the cystic duct, and common bile duct [17]. For up to 8 weeks of 
gestation, the extrahepatic biliary tree further develops through lengthening of 
the caudal part of the hepatic diverticulum [20]. In the 34-day of the embryo, the 
common hepatic duct is a broad, funnel-like structure in direct contact with the 
developing liver, without a recognizable left or right hepatic duct [17]. The distal 
portions of the right and left hepatic ducts develop from the extrahepatic ducts 
and are clearly defined tubular structures by 12 weeks of gestation. On the 
other hand, the proximal portions of the main hilar ducts derive from the first 
intrahepatic ductal plates [21]. The EHBDs and the developing intrahepatic 
biliary tree maintain luminal continuity from the very start of organogenesis 
throughout the development [21].  
During the first 7 weeks of human embryonic life, there is no IHBD system in 
the developing liver [17]. Around the eighth week of gestation, the primitive 
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hepatoblasts adjacent to the mesenchyme around the largest hilar portal vein 
branches increase the expression of cytokeratins (CK) 8, 18, and 19, and form 
cylindrical-sleeve cell-layer called “ductal plate” (Figura I.5) [22]. The ductal 
plate is a flat muralium of primitive biliary epithelium that develops in the 
mesenchyme along the branches of the portal vein. By 20 weeks of gestation, 
weak immunoreactivity for CK7 appears in the cells of the developing ducts 
[22]. The immunoreactivity for CK7 gradually increases and extends into more 
peripheral ducts [17], thus conforming the intrahepatic and hilar bile ducts. 
 
Figure I.5. Bile duct development through ductal plate formation (modified from Gordillo 
M et al, Development, 2015) [5]. 
 
I.2.3.2. Signaling pathways 
Several molecular pathways and transcription factors are involved in the 
differentiation of the liver and biliary tract. Among the key transcription factors, 
hematopoietically expressed homeobox (Hhex), hepatocyte nuclear factor 6 
(HNF6) and hepatocyte nuclear factor 1 beta (HNF1β) participate in the 
development of the liver and the biliary system [23-25]. Biliary cell differentiation 
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is induced in the fetal liver by a periportal gradient of activin/transforming growth 
factor-beta (activin/TGFβ) signaling, the extent of which is controlled by the 
inhibitory influence of HNF6 and the onecut factor 2 (OC2) [17, 26]. The Notch 
pathway may act in parallel or downstream of the activin/TGFβ signaling 
pathway to further support the biliary differentiation or to repress the hepatocytic 
differentiation program in these cells [17, 26]. 
The transcription factor sex-determining region y box (SOX) 17 seems to 
play also a key role in the differentiation of the biliary tree. Thus, in the week 8.5 
of murine gestation, SOX17 and the pancreatic and duodenal homeobox 1 
(PDX1) are essential for the differentiation of the biliary system and the ventral 
pancreas [16]. PDX1+ cells that begin to express SOX17 give rise to the 
development of the extrahepatic biliary system (i.e. gallbladder, common 
hepatic duct, cystic duct) and those that only express PDX1 result in the origin 
of the ventral pancreatic system [16]. Moreover, development of gallbladder 
further requires the expression of the forkhead box f1 (Foxf1) gene [17]. 
 
I.2.4. Cholangiocyte regeneration 
In humans, the regenerative origin of the mature biliary epithelial cells is 
dependent of their localization along the biliary tract. Thus, mature 
cholangiocytes may originate from differentiation of inmature cholangiocytes 
present in the channels of Hering, as well as from progenitor cells present in 
intrahepatic and extrahepatic peribiliary glands (PBGs) [27]. The PBGs are 
niches of stem/progenitor multipotent cells inserted in the walls of the bile tree. 
They can be localized in the whole bile tree, except in the gallbladder [28]. 
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However, similar cells −presumably committed progenitor cells− are found in 
the gallbladder, which express endoderm markers similar to those expressed by 
the peribiliary gland cells [6, 29]. The highest density of peribiliary glands is 
located at the cystic duct, the common hepato-pancreatic duct and the hilum 
common hepatic duct. These cells express classic endodermal transcription 
factors (i.e. SOX17, SOX9, FOXA2, HNF6, SALL4) and typical superficial 
markers of endodermal progenitors (i.e. EpCAM, NCAM, CD133) (Figure I.6) 
[27].  
A 
 
B  
 
Figure I.6. A) Peribiliary gland cells expressing nuclear SOX17. B) Culture of isolated 
cells from peribiliary glands expressing perinuclear SOX17 (red) and citoplasmic 
EpCAM (green), endodermal transcription factor and superficial marker, respectively 
[27].  
 
PBGs contain progenitor-like cells which normally proliferate and are 
responsible for the renewal of the surface epithelium-generating mature cells 
such as cholangiocytes, goblet cells (in the middle of the biliary tree), 
hepatocytes (near the liver) or islet cells (near the pancreas) [6]. The 
maturational process of the PBG cells shows a progress of decrease or loss of 
stem/progenitor cell markers and acquisition of mature cell markers [6]. 
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I.2.5. Cholangiopathies 
Cholangiocytes are also the central target of different diseases termed 
cholangiopathies, which in general show substantial morbidity and mortality. 
There are different types of cholangiopathies that can be subclassified 
according to their etiology in: a) immune-associated [i.e. primary biliary cirrhosis 
(PBC) [30] and primary sclerosing cholangitis (PSC) [31]], b) infectious (i.e. 
Cryptosporidium parvum) [32], c) genetic [i.e. polycystic liver diseases (PLDs) 
[33], cystic fibrosis (CF) [34] and Alagille´s syndrome [34]], d) vascular (i.e. 
postischemic cholangiopathies) [35, 36], e) idiopathic (i.e. biliary atresia [37] 
and sarcoidosis idiopathic childhood/adulthood ductopenia [38]), f) neoplastic 
(i.e. cholangiocarcinoma) [30], and g) drug-induced (i.e. fluorouracil-induced) 
[39, 40] (Figure I.7). Cholangiopathies share some common features such as 
inflammation, innate immune responses, cholangiocyte proliferation, as well as 
tissue repair processes.  
 
Figure I.7. Schematic representation of the main cholangiopathies. 
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I.3. Cholangiocarcinoma 
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with 
features of biliary tract differentiation. It is the second most frequent malignant 
liver tumor after hepatocellular carcinoma (HCC) and accounts for ~3% of all 
gastrointestinal cancers [41]. The incidence is increasing worldwide but differs 
between countries [42, 43]. Thus, Eastern countries such as Thailand, China 
and Korea show higher rates (>6/100.000) than Western countries (<4/100.000) 
[44]. CCA is generally diagnosed in elderly people (~60-70 years-old) and is 
more frequent in men than women [8].  
 
I.3.1. Classification 
I.3.1.1. Anatomical  
CCA is usually classified according to the anatomical localization as intrahepatic 
(iCCA), perihilar (pCCA), and distal (dCCA) (Figure I.8) [41, 45]. iCCA involves 
both hepatic ducts and proximal bile ducts, pCCA the perihilar bile duct, and 
dCCA the common bile duct [8]. pCCA is the most common type (~50%) 
followed by dCCA (~40%) and iCCA (~10%) [41]. 
 
Figure I.8. Anatomical localization of CCAs. Schematic figure showing the types of 
CCA according to the anatomical classification [41]. 
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I.3.1.2. Morphological  
Based on the gross appearance, iCCAs may exhibit three basic growth 
morphological patterns: i) mass lesion formation or “mass forming (MF)” in the 
liver parenchyma, ii) flat or nodular sclerosing growth of the affected bile duct 
with thickening of the duct wall and surrounding tissue and luminal stenosis, 
also named as “periductal infiltrating” (PI), and iii) intraductal growth (IG) in the 
bile duct lumen (Table I.1) [46-48]. 
 
Table I.1. Classification of CCAs according to the tumor morphology [48]. 
 
Growth patterns similar to PI or IG can be observed in pCCA and dCCA. 
However, pCCA usually adopt a nodular/PI growth pattern that represents the 
most frequent form (>80%) [49-51]. MF-iCCA generally occurs in chronic non-
biliary liver diseases and arises in peripheral small bile ducts, whereas PI and 
IG types exclusively involve large-hepatic bile ducts [52]. 
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I.3.1.3. Histological  
Histologically, the vast majority of pCCA and dCCA are mucinous 
adenocarcinomas. In contrast, iCCAs are highly heterogeneous tumors [52-55]. 
Thus, iCCAs show two main histological subtypes, reflecting their anatomical 
origin along the intrahepatic biliary tree: bile ductular type (mixed) arising from 
small intrahepatic bile ducts and bile duct type (mucinous) arising from large 
intrahepatic bile ducts [52-55]. Interestingly, this histological subclassification 
corresponds to different clinico-pathological features. The bile ductular type 
(mixed) iCCAs display an almost exclusively MF growth pattern [52-55], and are 
frequently associated with chronic liver diseases (i.e. viral hepatitis or cirrhosis) 
[56]. Notably, bile ductular type (mixed) iCCAs share clinico-pathological 
similarities with CK19-positive hepatocarcinoma (HCC) [54, 57]. 
 
I.3.1.4. Cells of origin  
CCAs of different locations exhibit pronounced heterogeneity, suggesting a 
potential different cellular origin [54]. The cell of origin is denominated as the 
normal cell that suffers the first cancer-causing mutation [58]. Possible cells of 
origin are hepatic stem cells, immature NCAM positive (NCAM+) 
cholangiocytes, mature (NCAM-) interlobular cholangiocytes, and peribiliary 
gland cells [59]. Additionally, the relationship between iCCA and combined 
HCC-CCA (cHCC-CCA) with hepatic progenitor cell (HPC) features highlights 
the potential participation of HPC in the development and progression of iCCA 
(Figure I.9) [54, 60].  
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Figure I.9. Differentiation process of progenitor hepatic cells into hepatocyte, 
cholangiocyte or intermediate cells, which may pathologically become transformed into 
HCC, CCA or cHCC/CCA [60].  
 
I.3.2. Risk factors 
Several risk factors have been described for CCA, but however, most of the 
patients do not show any of them associated [41]. The most relevant are 
cirrhosis, viral hepatitis B and C, PSC, liver fluke infection, hepatolithiasis, 
biliary malformations and congenital diseases, such as choledocal cysts, 
Caroli’s disease and congenital hepatic fibrosis. Moreover, general cancer risk 
factors such as elder-age, smoking, obesity or diabetes have also been 
described (Table I.2) [61-64]. Ethnic and environmental factors may also have 
important influence, particularly in the case of liver flukes. Hepatobiliary flukes 
such as Opisthorchis viverrini or Clonorchis sinensis are the main risk factors in 
Eastern regions and the leading cause of the high CCA incidence in these 
countries, due to their tradition of eating uncooked fish [44, 48, 65, 66]. Chronic 
exposure to toxins and/or chemicals may also be risk factors for CCA. Thus, the 
deposition in the liver of the radiographic agent thorotrast and the long-term 
exposure to high levels of chemicals such as dichloromethane and 1,2-
Introduction 
 
 
 
16 
dichloropropane have been shown to correlate with the development of CCA 
[67]. 
 
Table I.2. Known risk factors for CCA [41]. 
 
I.3.3. Symptoms and diagnosis 
CCAs are mostly asymptomatic in early stages of the disease. Thus, they are 
generally diagnosed in advanced stages, when the disease is widespread to 
other organs. Symptoms such as cholangitis, pruritus [68], jaundice, weight 
loss, abdominal pain, nausea/vomiting and fever may appear during the tumor 
progression [62]. Diagnosis is usually made by combining (Table I.3) [41]: i) 
imaging methods (Figure I.10) [i.e. computed tomography (CT), magnetic 
resonance imaging (MRI), endoscopic retrograde cholangiopancreatography 
(ERCP) or endoscopic ultrasound (EUS)], ii) analysis of non-specific serum 
tumor markers [i.e. carcinoembryonic antigen (CEA) and carbohydrate antigen 
19-9 (CA19-9)], and iii) histological analysis of tumor biopsies. 
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Table I.3. Symptons and approaches employed for the diagnosis of iCCA, pCCA and 
dCCA [41]. 
 
Abbreviations: CA19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; AFP: 
alpha-fetoprotein; CK7: cytokeratin 7; CA125: cancer antigen 125; CYFRA21-1: CK19 soluble 
fragments; MUC5AC: Mucin 5AC, oligomeric mucus/gel-forming; CA242: tumor marker 
antibody; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron 
emission tomography; PCT: percutaneous transhepatic cholangiography; ERCP: endoscopic 
retrograde cholangiopancreatography; EUS: endoscopic ultrasound. 
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A 
 
 
 
 
B 
 
 
 
 
C 
 
 
 
Figure I.10. Diagnostic imaging methods for CCA. (A) Images of intrahepatic CCA 
(arrow) by computerized tomography (CT) and magnetic resonance imaging (MRI). (B) 
Images of perihilar CCA (circle) by CT [dilatated bile ducts within the liver are shown 
(arrows)] and by cholangio-pancreato MRI. (C) Images of distal CCA (circle) with 
extended gallbladder (arrow) by CT (two sequential images) and cholangio-pancreato 
MRI [41]. 
 
 
I.3.4. Therapy  
CCAs are usually asymptomatic. They are generally diagnosed when the tumor 
is at an advanced stage and no possibilities of resection are possible due to its 
size and/or dissemination status [8, 44, 69, 70]. 
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I.3.4.1. Surgery 
Currently, the only potential curative options for CCA are the complete surgical 
resection of the tumor or the liver transplantation, although chances of 
recurrence are high [41]. Surgical resection of the tumor is indicated for those 
patients that follow a strict criteria based on tumor size, vascular involvement, 
metastasis, presence of liver cirrhosis and/or dysfunction, portal hypertension 
and the general condition of the patient [71]. Thus, CCAs are resectable if the 
vascular and biliary ductal involvement is limited to one lobe of the liver and if 
there is no extrahepatic disease in patients who are suitable for surgery [72]. 
However, the 5- and 10-year survival rate after surgery is low. 
 
I.3.4.2. Chemotherapy 
Classical chemotherapies are mainly palliative due to the high chemoresistance 
of CCA tumors. CCA tumors have a multidrug resistance (MDR) phenotype 
based on the activation of different mechanisms of chemoresistance (MOC). In 
healthy cholangiocytes, MOCs are involved in the cell defense against toxic 
compounds [73]. However, in CCA these mechanisms enhance 
pharmacological chemoresistance. Briefly, they include impaired uptake of  of 
sorafenib by inactivating mutations in organic cation transporter-1 (OCT-1) [74], 
as well as methotrexate, taxane and imatinib by organic anion-transporting 
polypeptide-1, A2 (OATP1A2) downregulation, implicated in lowering the 
intracellular amount of drug [75]. It has also been reported a poor response to 
gemcitabine and 5-fluorouracil (5-FU) associated with low expression of 
equilibrative nucleoside transporter 1 (ENT1) [76, 77] or inactivation of enzymes 
Introduction 
 
 
 
20 
such as thymidine phosphorylases (TPs) [78]. CCA chemoresistance has also 
been associated with reduced uptake of cisplatin due to modified expression of 
cationic aminoacid transporter 1 (CTR1)[79] and upregulation of B-cell 
lymphoma 2 (Bcl2) family members [80]. 
Furthermore, CCA chemoresistance is not only due to drug transport 
impairment, but also to strategies directed to repair or skip the damage 
produced by drugs, such as DNA lesions, mismatches, insertions and deletions. 
In CCA, DNA repair has been reported to be increased based on the 
upregulation of uracil-DNA glycosylase-1 (UNG1) [77]. On the other hand, DNA 
erroneous insertions or deletions in CCA are skipped because of a 
downregulation of proteins implicated in the mismatch repair (MMR) system, 
transforming CCA into a tumor with genetic instability, poorer prognosis and 
higher chemoresistance [81, 82]. 
 
I.3.4.3. Palliative  
Palliative therapies such as biliary stent placement and/or photodynamic 
therapy (PDT) are commonly employed in patients with CCA [61, 83]. 
Endoscopic stent placement is employed to restore the biliary drainage and 
relief cholestasis [84]. PDT can also improve quality of life [85, 86]. On the other 
hand, since radiation is associated with significant morbidity in these patients 
(i.e. biliary strictures, hepatic decompensation, etc.) it is not generally 
recommended for CCA [87].  
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I.3.5. Genetics and epigenetics  
I.3.5.1. Gene mutations 
CCAs are characterized by genomic instability and gene mutations. However, 
general genomic studies are often limited to selected classical oncogenes and 
tumor suppressors [88]. Regarding chromosomal instability, iCCA has been 
associated to copy number losses on chromosomal arms 1p, 4q, 8p, 9p, 17p 
and 18q, and copy number gains on chromosomal arms 1q, 5p, 7p, 8q, 17q and 
20q [88]. 
On the other hand, several genes downstream epidermal growth factor 
receptor (EGFR), including EGFR, are found mutated in CCA: i) activating 
mutations in EGFR (~15-20%) [89, 90], ii) hotspot activating missense 
mutations (9-32%) in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
subunit alpha (PIK3CA) [91, 92], and iii)  gain of function mutations in Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog (KRAS, 8-54%) [93, 94]. 
Other frequent gene mutations are found in TP53 (eCCA: 45%, iCCA: 35%), 
KRAS (eCCA: 40%, iCCA: 24%), ERBB2 (eCCA: 25%), SMAD4 (eCCA: 25%), 
FBW7 (eCCA: 15%), CDKN2A (eCCA: 15%), CDKN2B (eCCA: 15%), ARID1A 
(iCCA: 20%), IDH1 (iCCA: 18%), MCL1 (iCCA: 16%) and PBRM1 (iCCA: 11%) 
[95]. All the genetic alterations mentioned here, and many others identified also 
in CCA, have a deregulating effect in key networks, such as DNA repair, 
tyrosine kinase signaling, epigenetic remodelling factors, and so on. Among the 
altered key signaling pathways, a key pathway in cholangiocyte differentiation 
and biliary duct development, Notch, has been described to be deregulated in 
many cancers, including CCA, where it induces proliferation [96, 97].  Notch 
receptors (Notch 1-4) are usually overexpressed in CCA [96, 98]. Notch-4 
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overexpression has been correlated to poor survival in CCA patients[96] and 
the Notch inhibitor protein FBW7 is frequently inactivated by mutation in CCA 
[99]. 
Recurrent genetic variants have also been identified in the promoter of the 
human telomerase reverse transcriptase (TERT) in CCA [100]. Additionally, 
fibroblast growth factor receptor 2 (FGFR2) fusion gene products have also 
been reported, which are rare genetic alterations that have not been described 
in other liver cancers [101]. FGFR2 may fusionate with other genes creating 
mixed genes such as FGFR2-BICC1 [102, 103], FGFR2-KIAA1598 [102], 
FGFR2-TACC3 [103], FGFR2-AHCYL1 [102], FGFR2-MGEA5 [104], FGFR2-
KCTD1[105] and FGFR2-TXLNA [105]. Those fusions facilitate oligomerization 
and FGFR2 kinase activation, which result in increased cell proliferation [101].  
 
I.3.5.2. Epigenetic alterations 
Epigenetic abnormalities associated to DNA methylation, histone modifications 
(i.e. acetylation/deacelylation) and microRNAs (miRNAs) dysregulation have 
been described in CCA and seem to play a key role in the etiopathogenesis of 
this cancer. 
Patterns of aberrant DNA methylation have been reported in CCA, which 
affects complete chromosomes, such as a highly predominant hypermethylation 
on chromosome 2 or on the X-chromosome [106]. The expression of different 
genes has been described to be dysregulated in CCA due to promoter 
hypermethylation [107-110]. Several candidate genes of cancer-relevant 
signalling pathways have been identified. This is the case of the wingless and 
integration site (Wnt) signaling pathway target genes such as secreted frizzled-
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related protein (SFRP) members (SFRP1, SFRP2, SFRP4), DKK2, WNT3A and 
SOX17 [106]. Another hypermethylated gene in CCA is suppressor of cytokine 
signaling 3 (SOCS3), which downregulation is responsible for sustaining the 
interleukin-6/signal transducer and activator of transcription 3 (IL6/STAT3) 
signaling and for enhancing the expression of the prosurvival gene myeloid cell 
leukemia (MCL1), which results in survival of CCA cells [111]. 
According to these data, new epigenetic therapeutic strategies have been 
studied in order to reduce the DNA hypermethylation pattern in CCA. The most 
studied approach is the inhibition of DNA methyltransferase (DNMT) 1 activity 
[112]. The archetypal drugs used to inhibit DNMTs and thus promote genomic 
DNA demethylation are the azanucleosides azacytidine (5-azacytidine) and 
decitabine (2’-deoxy-5-azacytidine) [113]. Thus, DNMT1 inhibitors have 
successfully been used to revert in some CCA cell lines the expression of some 
downregulated genes, such as SFRP1, SFRP2, SFRP4, DKK2, WNT3A, 
SOX17[106] and SOCS3 [111]. The recovery of SOCS3 expression, for 
example, resulted in a reduction of CCA cell survival [111]. 
Histone acetylation is another epigenetic mechanism altered in CCA [107]. 
Some histone deacetylases (HDACs) appear to be upregulated, and induce cell 
proliferation [114]. Combined pharmacological and molecular treatment with 5-
FU and HDAC inhibitors (i.e. valproic acid, suberoylanilide hydroxamic acid) 
reduced the tumor capacity of some CCA cell lines [114]. In particular, 
overexpression of HDAC6 has been reported to promote the shortening of the 
primary cilium and the subsequent hyperproliferation in CCA, and experimental 
(shRNA) and pharmacological (tubastatin-A) inhibition restored the primary 
cilium and decreased CCA cell growth [115].  
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Some miRNAs contribute to cholangiocarcinogenesis through inhibition of 
tumor suppressor genes or by acting as oncogenes themselves [116]. 
Upregulation of miRs let-7a, 21, 26a, 34a, 421 and 494 has been reported in 
CCA, promoting cell proliferation mechanisms [40, 117, 118]. On the other 
hand, miRs 144 and 138 are downregulated in CCA, and their overexpression 
attenuate cell proliferation, migration and invasion [119]. Additionally, miR-148a 
and miR-152, reduced in CCA cells, decrease DNMT-1 expression, which may 
inhibit cell proliferation [120].  
Epigenetic changes are early events in the tumorigenesis. Therefore, novel 
approaches approaches for early detection and treatment are necessary. 
 
I.3.5.3. Developmental pathways involved in cholangiocarcinogenesis 
Different developmental pathways become activated during the process of 
cholangiocarcinogenesis and play a key role in the proliferation, migration and 
survival of the tumor cells. The Wnt/β-catenin and TGFβ1 pathways are among 
those with high activity.  
The Wnt/β-catenin signaling pathway has been described to be relevant in 
the development of the hepatobiliary system [5]. The canonical Wnt/β-catenin 
pathway is activated by the binding of Wnt ligands to frizzled receptors (Fzd) 
[121]. This interaction creates a chain reaction by which β-catenin activates 
through the phosphorylation of residues threonine (Thr) 41 and serine (Ser) 45 
(Figure I.11) [122]. Thus, β-catenin enters the nucleous to initiate the 
transcription of its target genes, which are related to proliferation, differentiation, 
migration, and so on [122]. However, when the pathway is repressed by wnt 
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ligand inhibitors (SFRPs, DKKs,…) or other mechanisms [123], β-catenin is also 
phosphorylated but in residues Ser33, Ser37 and Thr41, which enables its 
proteasomal degradation [122]. 
Different Wnt ligands bind to Fzd receptors favoring the cytoplasm 
accumulation and nuclear translocation of β-catenin [124], which leads to the 
formation of a complex of proteins that promotes the transcription of genes 
involved in carcinogenesis [125]. β-catenin is overexpressed in CCA [126] and 
intrinsic activating mutations have been described in few patients (8,3%: 2 of 24 
iCCA patients analyzed) [127, 128]. The high expression of Wnt ligands (i.e. 
Wnt3a, Wnt5a, Wnt7b, Wnt10a) in the inflammatory microenvironment of CCA 
is due, at least in part, by their secretion by activated macrophages [129, 130]. 
Thus, experimental inhibition of Wnt ligands release from macrophages reduces 
CCA tumor growth in a mouse xenograft model [130].  
 
Figure I.11. Scheme of the Wnt/β-catenin signaling pathway (modified from He X, 
2004, Development).[131]  
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The activity of TGFβ, similarly to Notch, Wnt, bone morphogenetic protein 
(BMP) and FGF, is necessary for the formation of cholangiocytes from 
hepatoblasts in embryonary development [5]. TGFβ proteins, for instance, are 
known to be ligands for serine-threonine kinase receptors I (TβRI) and II (TβRII) 
[132]. They are extracellularly secreted in an inactive state as prohormone, and 
utterly activated by cleavage due to the action of integrin-αvβ6, mannose-6-
phosphate receptors (MPRs), plasmin, metalloproteinases (MMPs 2 and 9), and 
thrombospondin-1 (TSP1) [132]. The activated TGFβ proteins bind to their 
receptors and activate a Smad-protein phosphorylation-cascade, which leads to 
the final activation of the transcription of their target genes (Figure I.12) [132]. 
Those target genes are implicated in the regulation of the deposition of the 
extracellular matrix (ECM), fibrogenesis, cellular growth, differentiation and 
modulation of immune response [132]. 
Among the TGFβ proteins the TGFβ1 plays a key role in the fibrogenesis of 
some liver cancers, such as HCC and hepatoblastoma [133, 134]. In adition,  
TGFβ1 promotes cell growth, invasion and metastasis of CCA [135, 136]. In 
CCA, TGFβ1 decreases the expression of miR-29a, which reduces cell growth 
and metastasis by inhibiting HDAC4 [135]. Moreover, in a thioacetamide (TAA) 
drug-induced rat model of CCA, TGFβ1 neutralization by anti-TGFβ-monoclonal 
antibodies reduces CCA growth [137]. 
 
Introduction 
 
 27 
 
Figure I.12. Scheme of the TGFβ signaling pathway (modified from the website of 
www.intechopen.com/books, Villapol S et al, 2013, DOI: 10.5772/53941). 
 
I.4. The transcription factor SOX17  
I.4.1. SOX proteins: general features 
The “sex-determining region of the Y-chromosome” (SRY) was the first SOX 
gene discovered in humans and mice [138, 139]. SRY protein presents a “high-
mobility group” (HMG) key for DNA-binding and common in all SOX family 
members [140]. The evolutionarily conserved HMG box is a 79 amino acid (aa) 
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DNA-binding motif [140] that mediates DNA-binding on a common consensus 
site [i.e. (A/T)(A/T)CAA(A/T)G] but with different levels of efficiency [141]. The 
HMG box of SOX proteins contains two independent nuclear localization signals 
and one leucine-rich nuclear export signal, which regulate the dynamic nucleo-
cytoplasmic shuttling of SOX proteins and result in the diverse subcellular 
distribution of SOX proteins during development [142-144]. In vertebrates, the 
SOX family includes more than 20 genes that are phylogenetically grouped in 
different subclasses (A-H) (Figure I.13) [145, 146].  
 
Figure I.13. A rooted phylogeny for the human SOX full-length aminoacid sequences 
[147]. 
 
Evidence from gain-of/loss-of-function studies in SOX genes revealed that 
they play key roles in tissue homeostasis, organogenesis and cell fate decision 
from embryonic to adult stages (Figure I.14) [147-150]. SOX proteins may also 
be regulated at 3 main levels: i) gene expression, which is cell-type and time 
specific within the developmental stages [149], ii) post-transcriptional and/or 
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post-translational modifications, altering their transactivation/transrepression 
features [151], and iii) regulation of recruited partner proteins, which not only 
influence the specific recognition of the binding sites of SOX-partner complexes 
on the target genes, but also determine transcription activities and significantly 
enhance the activation/repression potential [149, 152]. 
 
Figure I.14. The multiple roles of SOX proteins during development [147]. 
 
I.4.2. SOX proteins and cancer  
Many of the proteins governing the embryonic development are also involved in 
carcinogenesis. Similarly, different genes primarily described as crucial for 
carcinogenesis (i.e. oncogenes and tumor suppressor genes) are now also 
identified as essential for embryogenesis, indicating that both processes are 
intimately related [153]. Some examples of these events are the signal 
transduction pathways sonic hedgehog (Shh), TGFβ, Wnt/β-catenin and Notch, 
among others [153]. This close relationship has led to the proposition of the 
lineage-dependency theory, which argues that the cellular mechanisms that 
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govern lineage proliferation and survival during development might also underlie 
tumorigenic mechanisms [154]. Such a model could also be applied to the SOX 
family genes  (Figure I.15) [153, 155]. 
 
Figure I.15. Schematic representation of the SOX genes envolved in various cancer 
[153]. 
 
I.4.2.1. Oncogenic SOX proteins  
SOX family members may act as oncogenes or tumor suppressor genes, and 
sometimes as both depending on the cellular context. 
Introduction 
 
 31 
A subset of tumor cells, termed cancer stem cells (CSCs), has the ability to 
self-renew and to generate the diversity of cell types comprising the tumor. 
Accordingly, these cells carry stem-like properties and have the ability to sustain 
tumorigenesis continually [156]. CSCs are characterized by high levels of SOX2 
expression, which is a major stemness marker. SOX2 expression has been 
reported in different solid tumors, such as cervical carcinomas, sarcomas, 
gliomas, and breast and colorectal cancer [157-160]. SOX2 confers a 
dedifferentiated phenotype and may promote metastasis [158]. 
SOX4 was found among the set of genes uniquely upregulated in most 
cancer types relative to the normal tissues from which they arise, thereby 
contributing to a general gene expression signature of cancer [161]. SOX4 is 
upregulated in human acute leukemia [162], bladder tumors [163], lung cancer 
[164], in colorectal oncogenesis and is correlated with poor outcome in these 
patients [165, 166]. Interestingly, experimental knock-down of SOX4 induces 
apoptosis and growth suppression of certain tumor cells [167, 168].  
SOX9 is overexpressed in several human malignancies, such as brain, 
pancreas, colon, lung and prostate cancer [169]. The tumorigenicity of this 
transcription factor is, in part, due to its capability of regulating the CSC 
phenotype, preferentially in breast and brain tumors [170, 171]. In breast cancer 
cells, a high expression of SOX9 promotes the epithelial-to-mesenchymal 
transition (EMT) and metastases, and is associated with a poorer patient 
survival [170]. In spite of these observations, the role of SOX9 in oncogenesis is 
controversial and could be dependent on the cell context, even within the same 
type of cancer. This controversy may also be observed in breast cancer [172], 
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melanoma [173, 174], prostate cancer [175, 176], and bladder cancer [177, 
178].  
SOX11 appears to be a highly specific marker for mantle cell lymphoma 
(MCL), which is potentially useful for the differential diagnosis of MCL from 
other B-celllymphomas [179, 180]. Additionally, SOX11 is also overexpressed in 
lung cancers [181]. However, its role in glioma is controversial; some authors 
reported that SOX11 expression in the adult brain is reactivated during 
tumorigenesis [182], whereas others indicated that SOX11 inhibits 
tumorigenesis by inducing neuronal differentiation [183]. 
 
I.4.2.2. Tumor suppressor SOX proteins  
Different SOX proteins have also a tumor suppressor ability. In particular, SOX7 
acts as a tumor suppressor gene in prostate, colon, lung, and breast cancers 
through its involvement in cell death, movement, invasion and proliferation 
[184]. SOX15 (also known as SOX20) has also been identified as a potential 
tumor suppressor gene that inhibits the Wnt/β-catenin pathway in pancreatic 
ductal adenocarcinoma (PDAC) [184]. 
On the other hand, In mesenchymal breast cancer and in melanoma cells 
ectopic expression of SOX3 promotes the mesenchymal-to-epithelial transition 
(MET) program and impairs the cell mobility and invasion, suggesting that 
SOX3 has a tumor supressor role [185]. 
The role of SOX17 in cancer has been less extensively studied, but its 
potential role as tumor suppressor has been indicated in some tumor types.  
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I.4.3. SOX17  
The human SOX17 gene is located in a region of the chromosome 8p11.23 and 
has a length of ~3,900 base pairs [186]. Two DNA exons comprise the mRNA 
product with a coding region of 2,300 base pairs [186]. The promoter region of 
the SOX17 gene contains a frequently methylated CpG island that plays a role 
in regulating SOX17 gene expression [186]. The human SOX17 protein length 
is composed by 414 aa, characterized by an N-terminal HMG domain (67-138 
aa) and a C-terminal transactivation domain (195-413 aa) (Figure I.16) [186].  
 
Figure I.16. Three-dimensional structural representation of the SOX17 protein bound to 
DNA (acquired from the website of Research Collaboratory for Structural Bioinformatics 
Protein Data Bank, RCSB PDB, www.rcsb.org).  
 
I.4.4. SOX17 and biliary system development 
During embryogenesis, SOX17 is transiently expressed in the definitive 
endoderm during the initial phase of differentiation from mid-streak (7-day of 
gestation) to the early somite stages [187]. Interestingly, during the early somite 
(8.5-day of gestation) stages, SOX17 is re-expressed in the posterior-ventral 
foregut, where the progenitors of the gallbladder/bile duct are found [188] and is 
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maintained in the gallbladder primordium during the perinatal period [189]. In 
mice, Sox17-null embryos show a drastic reduction in endodermal cell 
population, and fail to develop beyond 10.5-day of gestation [187]. Cell-
autonomous Sox17 function in the foregut endoderm is required for the 
specification and differentiation of gallbladder/bile duct progenitors during 
foregut morphogenesis [16, 188]. Sox17 haploinsufficiency causes tissue-
autonomous defects in the morphogenesis and maturation of gallbladder and 
bile duct epithelia in mice, leading to congenital biliary atresia and subsequent 
acute hepatitis in late fetal stages [189]. The loss of Sox17 expression, not only 
produces gallbladder agenesia, but it also induces ectopic development of 
pancreatic tissue in the common bile duct [16, 188]. On the other hand, 
excessive Sox17 expression induces an ectopic biliary system development in 
positive PDX1 domains [16]. 
 
I.4.5. Other SOX17 functions 
SOX17 promotes the inhibition of the pluripotency of the embryonic stem cells. 
When embryonic stem cell pluripotency is achieved, octamer-binding 
transcription factor 4 (Oct4) switches from the Sox2 to the Sox17 promoter 
[190]. This switch allows the cells to turn off the pluripotency and generate a 
subset of endoderm-expressing Sox17 and Hex cardiac fate cells [190]. 
Additionally, SOX17 has an essential function in vascularization and arterial 
development. Sox17 is essential for the acquisition and maintenance of arterial 
identity, through Notch signaling activation (Figure I.17) [191]. 
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Figure I.17. SOX17 regulation of Notch signaling and artery development [191].  
 
I.4.6. SOX17 and diseases 
Abnormalities of SOX17 expression are not only relevant for the development of 
the biliary system, they are also important in several pathologies. Some 
mutations have been observed in SOX17, which induce SOX17 misregulation 
and diverse diseases. Congenital anomalies of the kidney and the urinary tract 
(CAKUT) represent a major source of morbidity and mortality in children and 
present the SOX17 mutation c.775T>A (p.Y259N), which promotes 
hyperactivation of the Wnt/β-catenin signaling pathway [192]. Additionally, a 
heterozygous SOX17 mutation (p.L194P) was also found in a sporadic 
colorectal cancer (CRC) cell line [193]. As in CRC, downregulation of SOX17 
expression is also found in other cancers, mostly due to promoter 
hypermethylation [194-196]. SOX17 downregulation triggers oncogenic signals 
in tumors such as colon [166] and breast cancer [194].  
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The expression of SOX17 is induced during the Wnt/β-catenin activation in 
the early stage of gastrointestinal tumorigenesis, and becomes downregulated 
by promoter methylation during malignant progression [197].  Hypermethylation 
of SOX17 promoter has been reported in different gastrointestinal tumors such 
as HCC [198], gastrointestinal carcinoma [197], CRC [196] and CCA [106]. 
However, the particular role of SOX17 in the pathogenesis of these tumors 
remains unknown. 
On the other hand, SOX17 is negatively related to kinesin family member 14 
(KIF14) expression in HCC tissues, and thus, by downregulating KIF14 
expression, SOX17 inhibits HCC cell proliferation and migration [199]. 
Moreover, SOX17 expression may also be downregulated by microRNAs, such 
as miR-141 in esophageal cancer [200] and miR-151 in prostate cancer [201]; 
on the other hand, SOX17 expression might be upregulated when miR-371-5p 
is overexpressed in CRC cell lines [202]. 
 
I.4.7. SOX17 and Wnt/β-catenin signaling pathway 
Accumulating evidence indicates that activation of Wnt/β-catenin signaling is 
one of the direct causes of tumorigenesis for several types of cancer. One of 
the SOX17 tumor suppressor activities is its potential capacity to antagonize the 
Wnt/β-catenin signaling [198]. In contrast to other factors that repress the Wnt 
signaling, such as SFRPs and DKKs, SOX17 may inhibit this pathway at a 
nuclear level [166]. SOX17 can interact with the transcriptional factors T-cell 
factor/lymphoid enhancer factor (TCF/LEF) and/or with β-catenin [195], 
repressing the transcription of cell cycle and proliferation related genes, and so, 
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inhibiting the function of Wnt signaling pathway [203, 204]. SOX17 contains 
both a transactivation domain in the C-terminal and a short functional motif 
(DxxEFD/EQYL) thought to be involved in the interaction with β-catenin [205]. 
SOX17 may also promote the degradation of both TCF and β-catenin proteins 
[166]. In relation with this last one, SOX17 allows the triple phosphorylation of β-
catenin at Ser33, Ser37 and Thr41, which enables its proteasomal degradation 
[206]. Furthermore, SOX17 might promote the expression of SFRP1, a Wnt 
ligand inhibitor, which impedes Wnt ligands to bind to the Wnt signaling Frizzled 
receptors [203].  
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The working hypothesis of this dissertation is that the transcription factor 
SOX17 may play a key role in the regulation of the biliary differentiation, and its 
downregulation may promote cholangiocarcinogenesis. These premises are 
based on the fact that: i) SOX17-/- mice show premature death due to alterations 
in the formation of the endoderm and severe biliary disorders (i.e. perinatal 
biliary atresia) [189], ii) SOX17 promoter was found hypermethylated in CCA 
tissue [106], iii) SOX17 acts as a tumor suppressor in different cancers (i.e. 
breast [194], gastrointestinal [197], hepatocarcinoma [198], etc.), and iii) SOX17 
may inhibit the protumorigenic Wnt/β-catenin pathway [198]. Thus, regulation of 
SOX17 expression in CCA could have potential therapeutic value. Based on 
this hypothesis, the following aims of study were proposed: 
I. Role of SOX17 in the differentiation of iPSC into mature 
cholangiocytes and in the regulation of the biliary phenotype. 
II. Analysis of SOX17 expression in CCA human tissue and cell lines 
compared to normal controls. 
III. Role of SOX17 in the pathogenesis of CCA and determination of the 
molecular mechanisms implicated using in vitro and in vivo (i.e. CCA 
xenografts in immunodeficient mice) experimental models. 
IV. Role of Wnt and TGFβ ligands in the SOX17 expression in cultured 
normal human cholangiocytes and molecular mechanisms involved. 
V. Restauration of SOX17 expression in CCA cells by using molecular 
and pharmacological demethylating tools. 
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M.1. Human samples 
Human liver samples were obtained from the Biobank of the Donostia University 
Hospital. The research ethical protocol was approved by the Ethical Committee 
for Clinical Research of Gipuzkoa and all patients signed a written consent for 
the use of their samples for biomedical research. In our study, we employed: 13 
CCA human biopsies (i.e. 11 iCCAs, 1 pCCA, 1 dCCA) as well as 14 normal 
human gallbladder tissues. 
Human liver samples were anonymously numbered and stored at -80ºC for 
further ribonucleic acid (RNA) isolation, and/or fixed in formaldehyde solution 
and embedded in paraffin for immunofluorescence analysis. 
 
M.1.1. Total RNA extraction  
Total RNA was isolated from small liver biopsies with Tri-Reagent® (Sigma). 
Briefly, 1 mL of Tri-Reagent® was added to every sample and homogenized by 
pipetting. Then samples were frozen at -80ºC. After 24 h, samples were thawed 
and 200 μL of chloroform (Sigma) were added to each tube. Tubes were 
vigorously shacked with a vortex for 30 seconds and incubated at room 
temperature for 10 min. Then, samples were centrifuged at 14,500 rpm for 15 
min at 4°C.  Subsequently, the aqueous phase was transferred into a new tube 
and the bottom phase was discarded.  0.5 mL of 2-propanol (Sigma) was added 
to the aqueous phase and incubated at room temperature for 10 min. Samples 
were centrifuged at 14,500 rpm for 10 min at 4°C and then the supernatant was 
removed. The pellet was washed with 1 mL of 75% ethanol (Sigma), briefly 
vortexed, and centrifuged at 14,500 rpm for 5 min at 4°C. After discarding the 
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supernatant, the pellet was left to dry at room temperature for 30 min. Finally, 
pellets were resuspended in 200 μL of UltrapureTM DNase/RNase-free distilled 
water (Invitrogen). RNA quantification was performed by ultraviolet (UV) 
spectrophotometry using the NanoDrop® V3.7 spectrophotometer (Thermo 
Scientific, ND-1000). 
 
M.1.2. Reverse transcription (RT)  
The RNA isolated from liver biopsies was converted into cDNA by using the 
SuperScript® VILO™ cDNA Synthesis Kit (Life technologies) in a C1000TM 
Thermal Cycler (Bio-Rad). Briefly, 1 μg of total RNA was incubated in a solution 
containing 2 μL of 10X SuperScript® Enzyme Mix, 4 μL of 5X VILOTM Reaction 
Mix and up to 20 μL final volume of UltrapureTM DNase/RNase-free distilled 
water. The RT was performed in three steps: i) 10 min at 25ºC, ii) 1 h at 42ºC, 
and iii) 5 min at 85ºC. The resultant cDNA was diluted with UltrapureTM 
DNase/RNase-free distilled water to a final concentration of 10 ng/µL.  
 
M.1.3. Histology 
Human liver biopsies we fixed in 4% formaldehyde solution (Sigma) for 24 h 
and afterwards embedded in paraffin (Merk Millipore). The resultant blocks were 
cut in 3-5 µm slices with a microtome and used for immunofluorescence 
techniques (see section M.5. Immunofluorescence). 
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M.2. Cell cultures 
M.2.1. Isolation and reprogramming of human myofibroblasts into 
cholangiocytes 
The following studies were carried out in collaboration with Dr. Robert C. 
Huebert at the Mayo Clinic (Rochester, Minnesota, USA). The research protocol 
was approved by the Ethical Committee for Research of Mayo Clinic and all 
patients signed a written consent for the use of their samples for biomedical 
research. 
Human myofibroblasts were isolated from biopsy specimens and then 
cultured and reprogrammed as previously described [207]. Briefly, isolated 
human myofibroblasts were transfected with vectors expressing OCT4, SOX2, 
kruppel-like factor 4 (KLF4) and myc protoncogene protein (cMYC) in order to 
induce stem cell pluripotency based on the Sendai system [208]. The induced 
pluripotent stem cells (iPSCs) were seeded in culture plates pre-coated with 
0.1% Matrigel (R&D systems) and with Nutristem xeno-free/feeder free (XF/FF) 
culture medium (Stemgent) supplemented with 16% mTeSR1 basal medium 
(Stemcell Technologies), mTeSR1 5X Supplement, 50X StemGS (ScienCell 
Research Laboratories) and 1% Penicillin/Streptomycin (P/S).  
The stepwise differentiation towards iPSC-derived cholangiocytes (iDCs) 
was performed by a process of temporal exposure to biliary morphogens. iPSCs 
were induced to definitive endoderm (DE) for 4 days using advanced Roswell 
Park Memorial Institute (RPMI) medium changed and supplemented daily with 
addition of 50 ng/mL Activin A and 50 ng/ml Wnt3a in the presence of Matrigel. 
For hepatic specification (HS), DE cells were treated daily with 10 ng/mL 
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fibroblast growth factor 2 (FGF2), 20 ng/mL bone morphogenic protein 4 
(BMP4) and 50 µg/mL sonic hedgehog (SHH) for 4 days. HS cells were induced 
to hepatic progenitor (HP) cells for 4 days with daily exposure to 50 µg/mL SHH 
and 100 µg/ml recombinant Jagged-1 (JAG1). To generate iDC, HP cells were 
treated for 4 days with H69 media (hormone-supplemented medium in the 
presence of NIH/3T3 fibroblast coculture) [209] changed and supplemented 
daily with 100 µg/mL TGFβ, and Matrigel was replaced by collagen. All growth 
factors were purchased from R&D Systems. 
 
M.2.2. Isolation of normal human cholangiocytes 
Normal human cholangiocytes (NHC) were isolated from bordering tissue 
samples obtained during surgery dissection of a local hepatic adenoma at the 
Mayo Clinic (Rochester, MN, USA); only tissue pieces informed as normal by an 
experienced pathologist were employed. 
The procedure to isolate and culture NHC was carried out according to a 
novel protocol described by our group [210]. Briefly, liver tissue was cut in small 
pieces (approximately 1 mm3) and placed in a 50 mL tube. Samples were 
digested for 30 min in a shaker bath at 37ºC with 25 mL of Dulbecco’s modified 
Eagle’s medium/Ham’s F-12 nutrient mixture (DMEM/F-12) medium (Invitrogen) 
supplemented with 3% of fetal bovine serum (FBS), 1% of P/S (both from 
Invitrogen), 0.1% of bovine serum albumin (BSA), 17 mg pronase, 12.5 mg type 
IV collagenase and 3 mg DNase (all three from Sigma). Digested tissue was 
sequentially filtered through 100 μm and 40 μm nylon meshes (Millipore, 
Bedford, MA). Trapped fragments between both meshes were collected, placed 
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in a new 50 mL tube and incubated again for another 30 min with the 
aforementioned solution, but substituting pronase with 13 mg hyaluronidase 
(Sigma). Afterwards, a second series of sequential filtrations were performed 
and intrahepatic bile duct units ranging from 40 μm to 100 μm were 
resuspended in fully supplemented DMEM/F-12 medium, named “FLASK 
medium” (Table M.1) and seeded on collagen-coated Cellstar flasks (Greiner 
Bio-One). 
 
M.2.3. Cholangiocarcinoma human cells  
We used 3 different CCA human cell lines in our experimental process: 
- EGI1 cell line was generated from a solid tumor of a 52-year-old 
Caucasian man with advanced malignant extrahepatic bile duct 
carcinoma and obtained from the “DSMZ German Collection of 
Microorganism and Cell Cultures”. 
- TFK1 cell line was generated from a surgical specimen of a 63-year-old 
Japanese man with extrahepatic bile duct carcinoma and obtained from 
the “DSMZ German Collection of Microorganism and Cell Cultures”. 
- Witt cell line (also known as SK-ChA-1) was generated from a malignant 
ascites of a patient with primary adenocarcinoma of the extrahepatic 
biliary tree [211], and so, can be considered as a metastatic extrahepatic 
CCA cell line [212].  
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M.2.4. Cell culture conditions 
Normal (NHC) and tumor (EGI1 and Witt) human cholangiocytes were cultured 
in “FLASK medium” (Table M.1). As exception, TFK1 cells were grown in a less 
enriched medium, which contained DMEM/F12+GlutamaxTM (Gibco) with 10% 
FBS (Gibco) and 1% P/S (Gibco), for a better growth. 
Table M.1. Composition of the FLASK medium 
Reagent Concentration Company  
DMEM/F12+Glutamax 89% (v/v) Gibco  
Fetal bovine serum 5% (v/v) Gibco 
MEM non-essential aa 1% (v/v) Gibco 
Lipid mixture 1000X 0.1% (v/v) Sigma 
MEM vitamin solution 1% (v/v) Gibco 
Penicillin/Streptomycin 1% (v/v) Gibco 
Soybean trypsin inhibitor 0.05 mg/mL Gibco 
Insulin transferrin selenium 1% (v/v) Gibco 
Bovine pituitary extract 30 μg/mL Gibco 
Dexamethasone 393 ng/mL Sigma 
T3 (3,3' 5-triiodo-L-thyronine) 3.4 μg/mL Sigma 
Epidermal growth factor  25 ng/mL Gibco 
Forskolin 4.11 mg/mL Ascent-Scientific 
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All the cell types were cultured on collagen-coated 25 or 75 cm2 flasks 
(Corning®) with their corresponding culture medium at 37°C and 5% CO2. 
Medium was refreshed every 48 h. When cells reached confluence, the cellular 
passage was performed as follows: 10 mL of Dulbecco’s phosphate buffered 
saline “DPBS” (Gibco) 1X were employed to wash the cells, prior to the addition 
of 1 mL of Trypsin-ethylenediaminetetraacetic acid (Trypsin-EDTA) 0.05% 
(Gibco) and subsequent incubation for 10 min at 37°C and 5% CO2. Afterwards, 
the solution containing cholangiocytes was centrifuged at 1,500 rpm for 5 min at 
4°C and the pellet resuspended in corresponding medium for subsequent 
seeding or in FBS with 10% dimethyl sulfoxide (DMSO) for freezing 
proceedings. Frozen vials were placed in a liquid nitrogen chamber for future 
needs. 
 
M.2.5. Whole cell extract processing 
M.2.5.1. Total RNA extraction 
300,000 cells were seeded on collagen-coated 6-well plates (Life technologies) 
and cultured with the corresponding cellular medium for 24 h at 37ºC and 5% 
CO2. Then, cells were washed with phosphatase buffered saline (PBS) 1X and 
1 mL of Tri-Reagent® was added into each well. The whole cell extract was 
collected and stored at -80ºC. The RNA extraction method was similar to that 
one employed for tissue samples and previously explained in section M.1.1. 
The only difference relies on the resuspension water type and volume. The 
extracted RNA from cells was resuspended in 10 µL of DNase/RNase Free 
water. 
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M.2.5.2. Reverse transcription (RT) 
1 μg of RNA was introduced in a 0.2 mL eppendorf tube. cDNA was obtained 
via RT with the M-MLV-RT protocol in a C1000TM Thermal Cycler (Bio-Rad). 
Briefly, RNA underwent DNase treatment (1 μL of DNase I Amplification Grade 
+ 1 μL of 10X DNase I Reaction Buffer) (Invitrogen) for 20 min at 37°C and then 
1 μL of 25 mM ethylene-diamine-tetra-acetic acid (EDTA; Invitrogen) was added 
to each tube (10 min at 65°C, 1 min at 90°C and kept at 4°C). Then, 30 μL of 
RT Mix [i.e., Buffer 5X, 8 μL; Random primers (RP, 100 ng/μL), 4 μL; 
deoxynocleoside triphosphates (dNTPs), 4 μL; dithiothreitol (DTT), 2 μL; RNase 
OUT (Invitrogen), 1.2 μL; M-MLV-RT (Invitrogen 1.2 μL; dH2O 9.6 μL)] were 
added to each tube and incubated under the following conditions: 37°C for 60 
min, 95°C for 1 min and kept at 4°C. The cDNA obtained was finally diluted to a 
final concentration of 10 ng/μL.  
 
M.3. Quantitative polymerase chain reaction 
The quantitative polymerase chain reaction (qPCR) was performed in a 7300 
Real-Time PCR System (Applied biosystems) with iQTM SYBR® Green 
Supermix (170-8880, Bio-Rad). Primers were purchased from Sigma (Table 
M.2). The mRNA expression level of every particular gene was determined by 
qPCR using 3 μL of cDNA (30 ng). Briefly, 0.6 μL of a 10 μM dilution of each 
primer (forward and reverse) and 10 μL of iQ™ SYBR® Green Supermix were 
added to the cDNA, and dH2O until reaching a final volume of 20 μL. The 
amplification was performed following the standard protocol:  
i) cDNA denaturation and activation of the enzyme at 95°C for 10 min.  
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ii) 40 cycles of 3 steps: cDNA denaturation at 95°C for 15 s, primers 
binding at 60°C for 30 s, and sequence extension at 72°C for 45 s. 
iii) acquisition of the melting or dissociation curve (95°C for 15 s and 60ºC 
for 1 min).  
The expression of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
gene was used as housekeeping and the control group was related to 100% of 
expression.  
Table M.2. Human primers used in qPCR. 
Primers Sequence 5'-3' 
CDK4 FW 
CDK4 RV 
ATGGCTACCTCTCGATATGAGC 
CATTGGGGACTCTCACACTCT 
Cytokeratin 7 FW 
Cytokeratin 7 RV 
ATCTTTGAGGCCCAGATTGC 
TTGATCTCATCATTCAGGGC 
Cytokeratin 19 FW 
Cytokeratin 19 RV 
CAACGAGAAGCTAACCATGC 
ATTGGCTTCGCATGTCACTC 
E-cadherin FW 
E-cadherin RV 
AATCCCCAAGTGCCTGCTTT 
ACCCCTCAACTAACCCCCTT 
Fibronectin FW 
Fibronectin RV 
GGGCAACTCTGTCAACGAAG 
CACACCATTGTCATGGCACC 
GAPDH FW 
GAPDH RV 
CCAAGGTCATCCATGACAAC 
TGTCATACCAGGAAATGAGC 
HDAC6 FW 
HDAC6 RV 
CGATGGACTTGGATGGTCTC 
GATGCTGACTACCTAGCTGC 
p16 FW 
p16 RV 
GGGGGCACCAGAGGCAGT 
GGTTGTGGCGGGGGCAGTT 
p21 FW 
p21 RV 
CGATGGAACTTCGACTTTGTCA 
GCACAAGGGTACAAGACAGTG 
S100A4/FSP-1 FW 
S100A4/FSP-1 RV 
ACGTGTTGATCCTGACTGCT 
CCTGTTGCTGTCCAAGTTGC 
SFRP1 FW 
SFRP1 RV 
CTACTGGCCCGAGATGCTTA 
GCTGGCACAGAGATGTTCAA 
SOX17 FW 
SOX17 RV 
GTGGACCGCACGGAATTTG 
GGAGATTCACACCGGAGTCA 
ZO-1 FW 
ZO-1 RV 
CGGTCCTCTGAGCCTGTAAG 
GGATCTACATGCGACGACAA 
 
(FW: Forward; RV: Reverse) 
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M.4. Western blotting 
Cells were seeded in a 6-well plate and left overnight (O/N) in quiescent 
medium (DMEM/F12+Glutamax, Gibco). The following day, cells were scrapped 
with 80 μL of radio-immunoprecipitation assay (RIPA) lysis buffer [150 mM 
sodium chloride (NaCl), 50 mM Tris pH 7.5, 0.1% SDS, 1% Triton-100X, 0.5% 
sodium deoxycholate, protease inhibitor cocktail tablet (Roche) and 
phosphatase inhibitors [1 mM ortovanadate, 10 mM sodium fluoride (NaF), 100 
mM β-glycerophosphate] and incubated at -80ºC O/N for cell lysis and protein 
extraction. Afterwards, cells were centrifuged at 14,500 rpm for 10 min at 4°C. 
Supernatant was employed for protein measurement.  
The protein concentration was measured using the PierceTM bicinchoninic 
acid (BCA) protein assay kit (ThermoFisher Scientific) according to the 
manufacturer´s instructions. Briefly, a 1/5 dilution of each sample (or just RIPA 
as a negative control) in dH2O was performed and placed in a 96 well plate. At 
the same time, a calibration curve was prepared [ranging from 0 to 1 mg/mL of 
BSA (Sigma)] and placed in the same plate. Afterwards, A and B reagents were 
mixed (in a 1:50 proportion respectively) and 200 μL were added to each well. 
The plate was incubated at 37°C for 30 min in darkness and subsequently 
measured in a Microplate Reader Multiscan Ascent® spectrophotometer 
(ThermoFisher Scientific) at a wavelength of 570 nm. 
Changes in protein expression were detected by immunoblotting using 20 μg 
of protein from whole cell extract in 7.5 or 12.5% sodium dodecyl sulfate 
polyacrilamide gel electrophoresis (SDS-PAGE), and electro-transferred to a 
nitrocellulose membrane (BioRad). Once blocked with 0.5% skim milk powder/ 
tris-buffered saline-5% tween (TBS-Tween) (Milk) or 0.5% BSA/TBS-Tween 
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(BSA), membranes were incubated O/N at 4°C with the appropriate primary 
antibody (Table M.3) at 1:1000 dilution in blocking solution (Milk or BSA). 
Horseradish peroxidase-conjugated secondary antibodies (Cell Signaling) at 
1:5000 dilution in blocking solution (Milk or BSA) were incubated for 2 h at room 
temperature and the Novex® enhanced chemoluminiscence  (ECL) horseradish 
peroxidase (HRP) Chemiluminiscent Substrate Reagent Kit (Invitrogen) used for 
further band visualization and quantitation with the ChemiDocTM MP System 
(Bio-Rad). The β-actin protein expression, or GAPDH in few cases, was used to 
normalize both the protein loading and expression. In some cases Ponceau S 
BioReagent (Sigma) was used to visualize the bands of the loaded proteins. 
 
M.5. Immunofluorescence 
M.5.1. Immunofluorescence in liver tissue samples 
Paraffin-embedded tissue samples were heated at 60ºC for 30 min and de-
waxed in xylene. Afterwards, rehydration was carried out in decreasing grades 
of ethanol (100%, 96%, 70% and 50%). Antigenic unmasking was performed by 
boiling the tissue samples in Citrate Buffer for 15 min. Samples were incubated 
O/N at 4ºC with the primary antibody in DPBS (1:100; Table M.3) or DPBS only 
as negative control. That step was followed by the incubation of the fluorescent 
secondary antibody (1:200) for 2 h and washed 3 times with DPBS. Finally, 
slides were mounted with a drop of VECTASHIELDTM mounting medium with 
40,6-diamidino-2-phenyindole (DAPI, Vector laboratories). Pictures were taken 
with a Nikon Digital Sight camera under a fluorescence microscope (Eclipse 80i, 
Nikon) with the NIS-elements AR 3.2 software or with a Zeiss LSM 510 confocal 
microscope [11].   
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Table M.3. Antibodies used for western blot and/or immunofluorescence. 
Antibody Company Reference Use 
Goat polyclonal anti-SOX17 R&D AF1924 WB, IF 
Mouse monoclonal anti-acetylated α-
tubulin Sigma-Aldrich T7451 IF 
Mouse monoclonal anti-CK7  Santa Cruz sc-23876 WB 
Mouse monoclonal anti-p-p53 (Ser15) Cell signaling #9286 WB 
Rabbit polyclonal anti-β-actin Cell signaling #4967 WB 
Rabbit polyclonal anti-β-catenin  Cell signaling #9581 WB, IF 
Rabbit polyclonal anti-γ-tubulin Abcam ab11320 IF 
Rabbit polyclonal anti-GAPDH Abcam ab22555 WB 
Rabbit polyclonal anti-KRT19 (CK19) ARP 10-P1335 WB 
Rabbit polyclonal anti-p21 Abcam ab7960 WB 
Rabbit polyclonal anti-p53  Novocastra (Leica) NCL-p53-CM1 WB 
Rabbit polyclonal anti-p-β-catenin 
(Ser33/37/Thr41) Cell signaling #9561 WB 
Rabbit polyclonal anti-pSAPK/pJNK 
(Thr183/Tyr185) Cell signaling #9251S WB 
Rabbit polyclonal anti-SAPK/JNK Cell signaling #9252 WB 
Rabbit polyclonal anti-SOX17 Abcam ab89954 IF 
Anti-rabbit IgG, HRP-linked Antibody  Cell signaling #7074 WB 
Anti-mouse IgG, HRP-linked Antibody  Cell signaling #7076 WB 
Donkey anti-goat IgG-HRP Santa Cruz sc-2020 WB 
Chicken anti-Goat IgG (H+L) Secondary 
Antibody, Alexa Fluor® 488 conjugate ThermoFisher A21467 IF 
Donkey anti-Goat IgG (H+L) Secondary 
Antibody, Alexa Fluor® 568 conjugate ThermoFisher A11057 IF 
Donkey anti-Mouse IgG Secondary 
Antibody, Alexa Fluor® 568 conjugate ThermoFisher A10037 IF 
Donkey anti-Rabbit IgG (H+L) Secondary 
Antibody, Alexa Fluor® 488 conjugate ThermoFisher A21206 IF 
 
Abbreviations: WB: western blot; IF: immunofluorescence 
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M.5.2. Immunofluorescence in cell cultures 
Cells were cultured on collagen-coated coverslips (Menzel-Gläser) in 24-well 
plates. Then, they were fixed with 1 mL of methanol for 10 min at -20ºC. 
Samples were washed 3 times with antigen retrieval solution (0.5% Triton-
100X/PBS 1X) and incubated for 20 min with this solution at room temperature. 
Next, cells were incubated with blocking solution (5% FBS/1% BSA/PBS1X) for 
30 min at room temperature and them with the primary antibody (1:100) (Table 
M.3) in 0.1% Triton-100X/1% BSA solution for 1 h. Afterwards, cells were 
washed 3 times with 1% BSA/PBS 1X solution and incubated under darkness 
with the corresponding fluorescent secondary antibody (1:1000) diluted in that 
same solution for 1.5 h. Finally, cells were washed 3 times with DPBS and 
coverslips were placed onto a microscope slide appropriate for 
immunofluorescence (Thermo Scientific) with a drop of VECTASHIELDTM 
mounting medium with DAPI (Vector laboratories). Immunofluorescence images 
were obtained with a Nikon Digital Sight camera under a fluorescence 
microscope (Eclipse 80i, Nikon) with the NIS-elements AR 3.2 software or with 
a Zeiss LSM 510 confocal microscope [11]. Immunofluorescence of ciliary-
associated proteins was performed in the same conditions but in cells under 7 
days of confluence.   
 
M.6. Viral vectors and small interfering RNAs 
M.6.1. SOX17 knock-down with lentiviruses (Lent-shRNA-SOX17) 
The expression of SOX17 was knocked-down in NHC with lentiviruses that 
constitutively express short hairpin RNAs (shRNAs) against SOX17 mRNA 
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(Lent-shRNA-SOX17; Santa Cruz Biotechnologies) and that contain the gene of 
resistance to puromycin. As a negative control, lentiviruses that constitutively 
express a shRNA-Control sequence (Santa Cruz) were used. The Lent-shRNA-
SOX17 contains a pool of three different expression constructs, each encoding 
target specific 19-25 nt (plus the hairpin sequence) designed to knock-down 
SOX17 gene expression (Table M.4). 
Table M.4: Sense and antisense sequences composing the pool of Lent-shRNA-
SOX17 constructs. 
shRNA-SOX17 Sequence 5'-3' 
Sc-38429-VA          
  Sense 
Antisense 
 
GCACGGAAUUUGAACAGUATT 
UACUGUUCAAAUUCCGUGCTT 
Sc-38429-VB        
    Sense 
Antisense 
 
GUCUGCCACUUGAACAGUUTT 
AACUGUUCAAGUGGCAGACTT 
Sc-38429-VC         
   Sense 
Antisense 
 
CCCAUAGUUGGAUUGUCAATT 
UUGACAAUCCAACUAUGGGTT 
 
M.6.2. SOX17 overexpression with lentiviruses (Lent-prEF1a-SOX17) 
Lentiviruses overexpressing SOX17 were produced in collaboration with the 
group of Prof. José Juan G. Marín (University of Salamanca, Salamanca, 
Spain). Briefly, human SOX17 open reading frame (ORF) was amplified from 
total RNA isolated from NHC cells by reverse transcription followed by high-
fidelity PCR using AccuPrime Pfx DNA polymerase (Life Technologies), specific 
primers (Table M.5) and an Eppendorf Mastercycle ep gradient S Thermal 
Cycler (Thermo Fisher). SOX17 cDNA was cloned into the PacI site of the pWPI 
lentiviral vector under the regulation of the constitutive elongation factor 1α 
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promoter. The identity of the cloning was confirmed by sequencing.  The pWPI 
lentiviral vector also contains the enhanced green fluorescent protein (eGFP) 
gene. Recombinant lentiviruses were produced in HEK293T cells (ATCC 
american type culture collection: CRL-11268) and using a standard 
polyethylenimine (PEI; Sigma) protocol. Thus, HEK293T cells were transfected 
with the pWPI-SOX17 vector or with the pWPI vector (negative control) and the 
packaging plasmids psPAX2 and pMD2.G. To form complexes PEI:ADN 6 µg of 
pWPI-SOX17 (or empty pWPI), 6 µg of psPAX2 and 4.5 µg of pMD2.G were 
dissolved in 1.2 mL of saline solution and 60 µL of PEI. After 20 min of 
incubation at room temperature, the mixture was added in the HEK293T culture. 
The following 3 days the supernatant was collected, and finally was filtered 
(0.45 µm pore size) and ultracentrifuged (53,000 g, 120 min, 16ºC). The 
lentivirus concentration was determined by infecting HEK293T cells with serial 
dilutions of the viral solution and the following analysis of eGFP-positive cells by 
a FACSCalibur flow cytometer (BD Biosciences). 
 
Table M.5. Primers used to SOX17 ORF amplification. 
SOX17 
primers Sequence 5'-3' 
Forward 
Reverse 
CCAAGGTTCCTTAATTAAGCCAAGATGAGCAGCCCGGATGCG 
GGAACCTTGGTTAATTAACTGTCACACGTCAGGATAGTTGCAGT 
 
 
M.6.3. Cellular lentiviral infection 
NHC were infected by lentiviruses carrying shRNA against SOX17 (Lent-
shRNA-SOX17) or Control (Lent-shRNA-control) at a MOI (multiplicity of 
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infection) of 1. After 24 h of incubation, media was changed and cell selection 
was performed with Puromycin dihydrochloride (from Streptomyces alboniger) 
suitable for cell culture (5 μg/mL; Sigma) (Figure M.5). On the other hand, CCA 
human cells (i.e. EGI1) were infected with lentiviruses carrying SOX17 (Lent-
SOX17) or empty viruses (negative control, Lent-control), at different MOIs (1, 
3, 5, 10, 15) and the appropriate MOI (3) was selected (Figure M.6). For Lent-
SOX17 and controls, once lentiviruses were added into the cell culture medium, 
the culture plate was centrifuged for 90 min at 32ºC and 1,800 g and the 
lentiviruses were kept in the culture medium overnight at 37ºC. In both cases 
(Lent-shRNA-SOX17 or Lent-SOX17), the infection was performed in the 
presence of Polybrene® (5 μg/mL, Santa Cruz). 
 
 
 
Figure M.5. Workflow for lentiviral infection with shRNA and selection of infected cells. 
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Figure M.6. Workflow for SOX17 overexpression in CCA cells using lentiviral infection. 
 
 
M.6.4. Inhibition of DNMT1 mRNA expression with siRNAs in normal 
human cholangiocytes and cholangiocarcinoma cells 
The DNMT1 mRNA expression was inhibited in both NHC and CCA (EGI1) 
human cells by using specific small interference RNA (siRNA) oligos against 
DNMT1 mRNA (siRNA-DNMT1; sc-35204, Santa Cruz Biotechnologies). In 
parallel, negative control siRNAs (siRNA-Control-A; sc-37007, Santa Cruz 
Biotechnologies) were also used. Cells were seeded in 12-well collagen-coated 
plates (100,000 cells/well) and transfected with siRNA-DNMT1 or siRNA-
Control using Lipofectamine RNAiMAX (Invitrogen). The transfection protocol 
was performed according to the manufacturer´s instructions. This transfection 
mixture was incubated O/N with the cells and the following day was replaced by 
FLASK-medium. NHC were treated, 24 h after transfection, with TGFβ1 (5 
ng/mL, R&D systems) or Wnt3a (100 ng/mL, R&D systems) in 1% P/S-DMEM 
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for 48 h and then cells were collected for RNA analysis. On the other hand, 
CCA (EGI1) human cells were collected 48 h after siRNA (siRNA-DNMT1 or 
siRNA-Control) transfection for RNA analysis. 
 
M.7. CCA xenograft animal model 
Immune-deficient nu/nu mice (Crl:NU-Foxn1nu; strain 088, homozygous) were 
purchased from Charles River Company to carry out CCA xenografts studies. 
These hairless animals (i.e. nude) are unable to produce T-cells because they 
have no thymus. All experimental procedures were approved by the Ethical 
Committee for Animal Experimentation of the “Diputación de Gipuzkoa” and 
were used in conformity with our institution’s guidelines for the use of laboratory 
animals. 
CCA (EGI1) human cells (100,000 cells in 100 µL of 1X PBS) were 
subcutaneously injected in the back of immune-deficient nu/nu mice. Three 
different conditions were studied: 
i)  EGI1 wild-type cells (CCA) were injected in both flanks of one mouse.  
ii) EGI1 cells infected with Lent-pWPI-Control (CCA Lent-control) were 
injected in the left flank of eight mice. 
iii)  EGI1 cells infected with Lent-pWPI-SOX17 (CCA Lent-SOX17) were 
injected in the right flank of the same previously mentioned eight mice.   
One month after the subcutaneous injection of the cells in immune-deficient 
nu/nu mice the first tumors started to be visible. Then, we measured the tumor 
size (length and wide) every three/four days and the tumor volume was 
calculated as described [213]: 
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Tumor Volume = (D x d2) / 2 
 Where “D” represents the largest diameter measured, and “d” the shortest 
 
Tumor measurements were carried out for 21 days, and animals were 
sacrificed when one of the mice showed a tumor volume of ~1.5 cm3 (maximum 
allowed by the Ethical Committee for Animal Experimentation). Tumors were 
extracted and the size compared after taking a picture with an Olympus SP-
590UZ camera (Olympus Imaging Corporation).  
All experimental procedures (i.e. injection of the cells, tumor measurements 
and sacrifice) were performed after anesthetizing the animals with isofluorane 
(2.5% in oxygen at a flow of 0.3 L/min) using an Inhalation Anesthetizing 
Equipment (Ohmeda). 
 
M.8. Cell death analysis 
Cell death was determined by using three different flow cytometry-based 
assays:  
i) Annexin-V (Alexa Fluor® 594 conjugate, Invitrogen) 
ii) Propidium Iodide ( Ex/Em=535/617, Invitrogen) 
iii) Caspase-3 activity (Phiphilux-G2D2, OncoImmunin® Inc)  
All fluorochromes did not interfere with the pWPI vector-derived lentivirus. All 
three assays were performed according to the manufacturer’s instructions and 
cells were equally seeded and infected. Briefly, 50,000 CCA (EGI1) and NHC 
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cells were seeded in each well of a collagen-coated 24-well plate, and infected 
with Lent-control or Lent-SOX17. Some cells were kept uninfected as controls.  
 
M.8.1. Annexin-V and propidium iodide 
48 h after infection, cells from each well were separated into two tubes for 
Annexin-V or Propidium Iodide staining. Then, they were centrifuged at 1,500 
rpm for 5 min at room temperature and washed once with cold PBS 1X at 1,500 
rpm for 5 min. The resulting pellet was incubated with 25 µL Annexin-V mixture 
for 15 min or 25 µL Propidium Iodide mixture for 30 min at room temperature. 
Finally, cells were resuspended in PBS 1X to a maximum volume of 160 µL 
(200-300 cells/µL) and analyzed by flow cytometry with the GUAVA EasyCyte 
8HT Benchtop flow cytometer (MerkMillipore).  
 
M.8.2. Caspase-3 activity 
48 h after infection, cells were centrifuged at 1,500 rpm for 5 min at room 
temperature and then incubated with 10 µL of Phiphilux-G2D2 for 30 min at 
37ºC. Next, they were washed once with Flow Cytometry Buffer at 1,500 rpm for 
5 min at room temperature. Finally, cells were resuspended in the same buffer 
to a maximum volume of 160 µL and analyzed with the Guava 8HT Benchtop 
flow cytometer. 
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M.9. Cell proliferation 
50,000 CCA (EGI1) cells were seeded in each well of a collagen-coated 24-well 
plate, and infected with Lent-control or Lent-SOX17. Some cells were kept 
uninfected as controls. 48 h after infection, cells were reseeded in a 96-well 
plate (5,000 cells per well). Cell proliferation was evaluated in the presence or 
absence of recombinant human Wnt3a protein (R&D systems) for 48 h by using 
the Cell Proliferation WST-1 Assay (Roche). Briefly, reseeded cells were 
incubated O/N at 37ºC in Flask medium. Next, cells were incubated with 
different doses of Wnt3a (ranging from 0 to 400 ng/mL) in 
DMEM/F12+Glutamax, 1% FBS and 1% P/S for 48 h. Then, 10 μL of water 
soluble tetrazolium salt 1 (WST-1) were added to each well, incubated at 37ºC 
for 1 h and the colorimetry read at a wavelength of 450 nm in a Multiskan 
Ascent spectrophotometer. 
 
M.10. Cell senescence  
20,000 NHC cells (at passages ~5, ~10 and ~15, and passage 5 NHC 
uninfected or infected with Lent-shRNA-SOX17 or Lent-shRNA-control) were 
seeded in each well of a collagen-coated 24-well plate. After 48h of incubation, 
cells were washed with PBS 1X and the senescence β-galactosidase kit (Cell 
signaling) protocol was followed according to the manufacturer’s instructions. 
Briefly, cells were fixed with 1X fixation solution for 10-15 min at room 
temperature, washed two times with PBS 1X and incubated with β-gal staining 
solution O/N at 37ºC in darkness in the absence of CO2. Finally, cell staining 
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images were obtained with a Nikon D90 camera coupled to an Eclipse TS100 
light microscope (Nikon). 
 
M.11. Cell migration 
50,000 CCA (EGI1) cells were seeded in each well of a collagen-coated 24-well 
plate, and infected with Lent-control or Lent-SOX17. Some cells were kept 
uninfected as controls. After cell death was observed, the remaining living cells 
were reseeded (200,000 cells/well) in a collagen-coated 6-well plate with 
DMEM/F12+Glutamax and 1% P/S. Once cells reached confluence, three 
longitudinal scratches were done to the surface of each well with a 10 µL pipette 
tip and cell migration was monitored every four hours with a Nikon Eclipse TS-
100 light microscope. At 24 h cells were fixed and stained with crystal-violet 
(Sigma) in 4% formaldehyde and images were obtained with a Nikon D90 
camera coupled to a Nikon Eclipse TS-100 light microscope. Finally, the well 
surface not covered with cells was compared in each condition by using the 
Image J software. 
 
M.12. Cell redox stress  
Levels of oxidative stress were determined in both NHC and CCA (EGI1) cells, 
after inhibiting (Lent-shRNA-SOX17) or overexpressing SOX17 (Lent-SOX17), 
by using the CellROX® “Deep Red” Flow Cytometry Assay Kit (Invitrogen) 
according to the manufacturer’s instructions. Briefly, 50,000 cells were seeded 
in collagen-coated 24-well plates and infected with the corresponding lentivirus 
for 48 h. Then, cells were trypsinized and centrifuged at 1,500 rpm for 5 min at 
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room temperature. The pellet of cells was resuspended with 250 µL of 250 µM 
CellROX Deep Red, incubated for 30 min at 37ºC and centrifuged at 1,500 rpm 
for 5 min at room temperature. Finally, cells were resuspended in PBS 1X to a 
maximum volume of 160 µL (200-300 cells/µL) and analyzed by flow cytometry 
with the GUAVA EasyCyte 8HT Benchtop flow cytometer. As a negative control, 
cells were incubated at 37ºC with 5 mM of the antioxidant N-acetylcysteine 
(NAC) for 1 h, and as a positive control cells were incubated at 37º C with 800 
µM (NHC) or 2 mM (EGI1) of the oxidative stress inducer ter-butyl 
hydroperoxide (THBP) for 30 min. 
 
M.13. Illumina mRNA expression array 
Illumina_human_v6.2 gene expression arrays were carried out in NHC and 
CCA (EGI1) cells in collaboration with Dr. Ana María Aransay and Dr. Jose Luis 
Lavín (Genome Analysis Platform of CICBigune, Zamudio). NHC uninfected or 
infected with Lent-shRNA-SOX17 or Lent-shRNA-control (as described in 
section M.6.3) were collected 1 week after infection. On the other hand, CCA 
cells, both uninfected and infected with Lent-SOX17 or Lent-control (as 
described in section M.6.3) were collected 6 h after infection.  
 
M.13.1. Total RNA isolation protocol 
The miRNeasy Micro kit (Qiagen) was used for total RNA isolation following the 
manufacturer’s instructions. Briefly, cells were incubated with 1 mL of Qiazol 
and then collected into a 1.5 mL Eppendorf tube. Cell extracts were 
homogenized with a vortex for 1 min and incubated at room temperature for 5 
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min. Then, 140 μL of chloroform were added and the tube was shacked 
vigorously for 15 s and incubated at room temperature for 2 additional min. 
Tubes were centrifuged at 12,000 g at 4ºC and the upper colorless phase 
transferred into a new tube. Afterwards, absolute ethanol was added and mixed 
thoroughly. The resultant solution was transferred into an “RNeasy MinElute” 
spin column introduced in a 2 mL collection tube and then centrifuged of 8,000 
g for 15 s at room temperature. The flow-through solution was discarded and 
the RNA trapped into the column was washed with 350 μL of Buffer RWT 
(prepared with isopropanol) by centrifugation at 8,000 g for 15 s at room 
temperature. The column was then treated with 80 μL of DNase I/Buffer RDD 
for 15 min at room temperature and after washed twice with 500 μL of Buffer 
RWT (prepared with isopropanol) at 8,000 g for 15 s at room temperature and 
with 500 μL of Buffer RPE at 8,000 g for 15 s at room temperature. For the last 
washing step, 500 μL of 80% ethanol were added onto the RNeasy MinElute 
spin column, centrifuged for 2 min at 8,000 g. The column-membrane was dried 
by centrifugation at full speed for 5 min and then 15 μL of RNase-free water was 
added directly to the center of the spin column membrane and centrifuged for 1 
min at full speed to elute the RNA. This last step was repeated twice to recover 
a higher amount of RNA. 
 
M.13.2. Illumina gene expression array 
The whole human genome expression was evaluated in NHC and CCA (EGI1) 
cells total RNA by using the Illumina_human_v6.2 gene expression array 
(Illumina Inc.). The RNA to use in the arrays required a high level of quality. 
That is why several quality controls were performed: i) 260/280 nm wavelength 
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ratio, to determine the purity of the sample, and ii) RNA Integrity Number (RIN) 
measurement in a RNA Nano Chip Bioanalyzer (Agilent Technologies), to 
determine the degradation level of the sample. The total RNA isolated from the 
cells had a 260/280 nm wavelength ratio between 1.8 and 2.0, and showed a 
RNA integrity number (RIN) over 8.0, meaning no degradation. The 
concentration of the total RNA was evaluated by a Qubit® 2.0 Fluorimeter 
(ThermoFisher Scientific), and 200 ng of each sample RNA were used for the 
array. The cRNA synthesis, amplification, labeling and hybridization of the 
samples were performed following the Whole-Genome Gene Expression Direct 
Hybridization protocol (Illumina Inc.).  
The cRNA of the samples were hybridized to the diverse gene-probes of the 
array and the differential gene expression levels in the diverse samples were 
detected by a HiScan scanner (Illumina Inc.). The crude data acquired from the 
scanner was uncodified with a GenomeStudio analysis and exported as a 
spp2.txt file for its further statistical analysis performed at the Genome Analysis 
Platform of CICBigune (Zamudio).  
 
M.13.3. Volcanoplots and heatmaps 
In statistics, a volcanoplot is a type of scatter-plot that is used to quickly identify 
changes in large datasets composed of replicate data [214]. It plots log10 
statistical significance (log10 p-value) versus log2 fold-change on the y- and x-
axes, respectively [214]. These result in datapoints with low p-values (highly 
significant) appearing toward the top of the plot, and expression changes 
toward the right and left sides of the plot equidistant from the center [215]. 
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Meaning, the volcanoplots show the genes significantly upregulated or 
downregulated in one sample in comparison with another one. 
Heatmap is a graphical 2-dimentional representation of data where the 
individual values contained in a matrix are represented as colors. Higher values 
are represented by small dark red squares, lower values by blue squares and 
medium values as white squares. The results of a cluster analysis displayed by 
permuting the rows and the columns of a matrix to place diverse genes with 
similar values near each other according to the clustering.  
 
M.13.4. Gene expression analysis 
The RNA array statistical analysis provides three lists of the expression levels 
according to the different gene-probes present in the array plate. The first list is 
a representation of all the expression levels of the whole pool of gene-probes, 
and is called Table. Another list is filled by all the gene-probes which 
represented the best p-value of the expression compared between the samples, 
and is called Table_BestP. However, to have the best p-value does not mean 
that the gene represented by that probe is significantly differentially expressed. 
The last list shows the real differentially expressed genes, both the upregulated 
and downregulated ones, and is called Table_WonNR. This list, by an 
algorithm, considers both the fold-change and the adjust p-value of each 
sample in order to verify the real expression differences. 
The gene function analysis was performed with diverse database programs 
such as Panther (WebGestalt, String), Pubmed, Uniprot and Genecards. 
Moreover, we used Gene Ontology and Kegg programs to test potential 
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association of the differentially-expressed genes on metabolic pathways and/or 
intracellular interactions. 
 
M.14. Statistical analysis 
All results of the study were collected in MS Excel tables for subsequent 
statistical analysis using the GraphPad program. For comparisons between two 
groups, statistical parametric t Student test or non-parametric Mann-Whitney 
test were used. For comparisons between more than two groups, 
nonparametric Kruskal-Wallis test followed by a posteriori Dunns test or the 
parametric test One-Way ANOVA followed by a posteriori Bonferroni test were 
used. The differences are considered significant when p<0.05.  
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R.1. The reprogramming of induced pluripotent stem cell (iPSC) into 
cholangiocytes is dependent on SOX17 
In the last years, iPSC reprogramming has emerged as a potential tool for 
regenerative medicine [216, 217]. Very recently, human myofibroblats were 
genetically modified to produce iPSCs, and then further reprogrammed into 
normal cholangiocytes [207]. In this context, human myofibroblasts were 
differentiated into a pluripotent phenotype by transient-forced expression of the 
transcription factors OCT4, SOX2, KLF4 and c-MYC to obtain iPSCs, and then 
these cells were reprogrammed into normal cholangiocytes (i.e. induced 
differentiated cholangiocytes, “iDCs) by using a multistep process with exposure 
to biliary morphogens. As indicated in the Material and Methods section, this 
protocol contains five subsequent steps: i) iPSCs, ii) definitive endoderm (DE), 
iii) hepatic specification (HS), iv) hepatic progenitor (HP) and v) iDCs (Figure 
R.1.A). These iDCs recapitulate different biliary features such as the mRNA and 
protein expression of CK7, CK19, polycystic kidney disease 2 (PKD2), cystic 
fibrosis transmembrane conductance regulator (CFTR) and anion exchanger 2 
(AE2), as well as the presence of the cholangiocyte primary cilium [207]. 
In our approach, we found that SOX17 protein expression is highly induced in 
the last step of the reprogramming phase, similarly to the biliary markers CK7 
and CK19, corresponding to the biliary differentiation (i.e. iDCs) compared to 
the previous steps (i.e. HS and HP) (Figure R.1.B). Based on these data, we 
evaluated the potential role of SOX17 in the regulation of the biliary 
differentiation. For this purpose, we knocked-down SOX17 expression in the 
three phases of the iDC reprogramming protocol (i.e. between DE-HS, HS-HP 
and HP-iDC) by using lentiviruses overexpressing shRNAs against SOX17 
Results 
 
76 
 
(Lent-shRNA-SOX17) (Figure R.1.A). On the other hand, we used Lent-shRNA-
control or non-infected cells as controls (Figure R.1.A). Infection with Lent-
shRNA-SOX17 downregulated the high induction of SOX17 protein expression 
in the iDC phase partially, but significantly. Notably, the knock-down of SOX17 
protein expression resulted in decreased protein expression of CK7 and CK19 
biliary markers (Figure R.1.B-C). These data strongly supported the hypothesis 
that SOX17 is a key transcription factor regulating cholangiocyte differentiation. 
  A 
 
B 
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Figure R.1. Protein expression of biliary markers over the differentiation of iPSCs into 
iDCs. A) Workflow of iPSC differentiation into iDCs and timepoints of SOX17 inhibition 
with Lent-shRNA-SOX17. B) western blot and C) densitometry quantitation showing 
SOX17, CK7 and CK19 protein expression. GAPDH was used as a normalizing loading 
control for the western blot.  
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R.2. The expression of SOX17, and other biliary markers, decreases in 
normal human cholangiocytes over the cellular passages in vitro and runs 
in parallel with increased cell senescence 
Normal human cholangiocytes (NHC), similarly to other primary cultures, 
progressively lose epithelial markers of differentiation along cell passages and 
gradually enter in senescence [218]. The analyses of expression in NHC 
revealed that SOX17 mRNA (Figures R.2) and protein (Figures R.3) both 
decrease over cell passages in vitro. Similarly, the expression of specific 
cholangiocyte markers within the liver such as CK7 and CK19, as well as the 
expression of the epithelial marker E-cadherin, all decreased in NHC over cell 
passages in vitro (Figures R.2). 
 
Figure R.2. Relative mRNA expression of biliary epithelial markers (SOX17, CK7, 
CK19 and E-cadherin) in NHC over cell passages in vitro. P: number of cell passages 
in vitro. n=number of samples in each condition. GAPDH was used as housekeeping 
normalizing gene.  
 
On the other hand, increased expression of senescence markers was 
observed in NHC over cell passages in vitro, which run in parallel with 
decreased expression of biliary epithelial markers. In particular, progressive 
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overexpression of the senescence marker p21 protein occurs together with the 
downregulation of SOX17 protein in NHC over cell passages in vitro (Figure 
R.3).  
A 
 
 
B                                                    
 
Figure R.3. Relative expression of SOX17 and p21 proteins in NHC over the cell 
passages in vitro. A) Representative western blot showing the expression of SOX17 
and p21 proteins in NHC over cell passages (5, 10 and 15) in vitro. B) Relative SOX17 
and p21 protein expression in NHC over cell passages (5, 10 and 15) in vitro. β-actin 
was used as normalizing loading control. P: number of cell passages in vitro. n=number 
of samples in each condition.  
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Additionally, the analysis of expression of cell cycle-related proteins that 
participate in the regulation of senescence was performed. Thus, the mRNA 
expression of the cyclin-dependent kinase 4 (CDK4), which promotes cell cycle 
and cell division, was found downregulated in NHC over cell passages in vitro 
(Figure R.4). In contrast, the expression of the CDK4 inhibitor p16INK4a, which 
inhibits cell cycle promoting senescence [219], increased in NHC over cell 
passages in vitro (Figure R.4). 
 
Figure R.4. Relative mRNA expression of CDK4 and p16ink4a, in NHC over cell 
passages in vitro. GADPH was used as housekeeping normalizing gene. P: number of 
cell passages in vitro. n=number of samples in each condition.  
 
All these data were also associated with increased β-galactosidase activity 
in NHC over the cell passages in vitro (Figure R.5), which is also a marker of 
cell senescence [220]. 
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Figure R.5. Representative staining of β-galactosidase activity in NHC over the cell 
passages in vitro. A) Light microscopy images showing β-galactosidase activity in NHC 
in blue over the cell passages (8, 11 and 15) in vitro. B) Relative β-galactosidase 
activity in NHC over the cell passages (8, 11 and 15) in vitro. P: number of cell 
passages in vitro. n=number of samples in each condition.  
 
R.3. SOX17 regulates CK7 and CK19 expression in normal human 
cholangiocytes but does not influence the senescence process 
In order to further demonstrate the role of SOX17 as regulator of cholangiocyte 
differentiation, and to test its role in senescence, the expression of SOX17 was 
experimentally downregulated by infecting NHC low passages with Lent-
shRNA-SOX17 (Lent-shRNA-control and non-infected cells were used as 
controls) as described in Materials and Methods (M.6.3 section). NHC low 
passages (between 5-8 passages) showed high basal expression levels of 
SOX17. Infection of NHC low passages with Lent-shRNA-SOX17 resulted in 
downregulation of both SOX17 mRNA and protein expression compared to cells 
infected with Lent-shRNA-control or non-infected cells (Figure R.6). 
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Figure R.6. Relative SOX17 expression in NHC low passages (between P5-8) infected 
with Lent-shRNA-SOX17, Lent-shRNA-control or non-infected. A) Relative SOX17 
mRNA expression. GADPH was used as housekeeping normalizing gene. B) 
Representative western blot of SOX17 and relative SOX17 protein quantification. β-
actin protein was used as a normalizing loading control. n=number of samples in each 
condition.  
 
In addition, experimental knock-down of SOX17 in NHC with Lent-shRNA-
SOX17 prompted the downregulation of both CK17 and CK19 mRNA 
expression compared to the experimental control conditions (Figure R.7), 
indicating that SOX17 regulate the maintenance of expression of both biliary 
markers in NHC in culture.  
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Figure R.7. Relative CK7 and CK19 mRNA expression in NHC low passages (between 
P5-8) infected with Lent-shRNA-SOX17, Lent-shRNA-control or non-infected. GADPH 
was used as housekeeping normalizing gene. n=number of samples in each condition.  
 
In contrast, experimental knock-down of SOX17 in NHC with Lent-shRNA-
SOX17 did not affect senescence, as no changes in p21 protein, β-
galactosidase activity (Figure R.8), and CDK4 or p16INK4a mRNA levels were 
observed compared to the experimental control conditions (Figure R.9). 
Additionally, only the lentiviral infection increased the p21 protein expression in 
NHC showing no differences between Lent-shRNA-control and Len-shRNA-
SOX17 (Figure R.8). 
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Figure R.8. SOX17 does not affect the senescence process of NHC in culture. A) 
Representative western blot (left) and relative expression (right) of SOX17 and p21 
proteins in NHC infected with Lent-shRNA-SOX17, Lent-shRNA-control or non-
infected. β-actin was used as normalizing loading control. B) Light microscopy images 
(left) and relative β-galactosidase staining activity (right) in NHC infected with Lent-
shRNA-SOX17, Lent-shRNA-control or non-infected. n=number of samples in each 
condition. 
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Figure R.9. Relative CDK4 and p16INK4a mRNA expression in NHC infected with Lent-
shRNA-SOX17, Lent-shRNA-control or incubated with vehicle solution. GADPH was 
used as housekeeping normalizing gene. n=number of samples in each condition. 
 
 
R.4. Experimental downregulation of SOX17 in normal human 
cholangiocytes promotes their Wnt-dependent proliferation. 
Recent reports indicated that SOX17 could be involved in the negative 
regulation of the Wnt/β-catenin pathway [198]. Based on this data, we 
investigated the implication of SOX17 on the proliferation-regulating role of the 
Wnt/β-catenin pathway in NHC in culture. The inhibition of SOX17 alone already 
induced NHC proliferation (Figure R.10.A). The presence of the Wnt3a ligand 
did not affect the proliferation of NHC infected with Lent-shRNA-control or non-
infected. However, notably, the Wnt3a ligand promoted the proliferation of NHC 
previously infected with Lent-shRNA-SOX17 (Figure R.10.B); this event was 
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associated with decreased mRNA levels of SFRP1, a protein that binds to and 
inhibits the Wnt ligands (Figure R.11). 
A  
 
B 
 
Figure R.10. A) Relative proliferation of NHC in NHC infected with Lent-shRNA-SOX17, 
Lent-shRNA-control or non-infected. B) Relative proliferation of NHC in NHC infected 
with Lent-shRNA-SOX17, Lent-shRNA-control or non-infected in the presence or 
absence of Wnt3a.  
 
 
 
 
Figure R.11. Relative SFRP1 mRNA expression in NHC infected with Lent-shRNA-
SOX17, shRNA-control or non-infected. GADPH was used as housekeeping 
normalizing gene. n=number of samples in each condition.  
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R.5. SOX17 expression is reduced in CCA human tissue 
Based on our aforementioned data demonstrating that SOX17 regulate 
cholangiocyte differentiation and the maintenance of the biliary phenotype, we 
evaluated the expression of SOX17 in CCA human samples compared to 
diverse controls. Since normal human liver biopsies are mainly composed of 
hepatocytes, which show very low expression of SOX17 [221], the SOX17 
mRNA levels in CCA human tissue were compared to both low passages of 
NHC and normal gallbladder human tissue (which is highly composed by 
cholangiocytes) [222]. Our data revealed that SOX17 mRNA expression levels 
are lower in CCA human tissue than both NHC in culture and normal 
gallbladder human tissues (Figure R.12). 
 
 
Figure R.12. Relative SOX17 mRNA expression in NHC in culture, normal human 
gallbladder tissues and CCA human samples. GAPDH was used as housekeeping 
normalizing gene. Dots represent independent patient’s samples and bars indicate the 
mean value. 
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In addition, SOX17 protein expression was evaluated by 
immunofluorescence in both normal human livers and iCCA human tissues. In 
normal human livers, CK19-positive cells (i.e. cholangiocytes) show high 
expression of SOX17 (Figure R.13). At the cellular level, SOX17 ewas present 
at the perinuclear and nuclear level. In contrast, the expression of SOX17 was 
found almost absent in human iCCA cells, which stained positively for CK19 
(Figure R.13). 
 
 
Figure R.13. Representative images of immunofluorescence showing SOX17 
expression in normal human liver and iCCA human tissue. Expression of CK19 and 
SOX17 are indicated in red and green, respectively. Number of normal liver biopsies 
and iCCA human tumors analyzed = 5 in each condition. 
 
R.6. CCA human cells show decreased SOX17 expression compared to 
normal human cholangiocytes in culture 
We further evaluated the expression of SOX17 in three different CCA human 
cell lines (EGI1, TFK1 and Witt) compared to NHC in culture. Similarly to the 
previous observations using human liver and CCA samples, SOX17 mRNA and 
protein expression was found highly downregulated in all three types of CCA 
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human cells compared to NHC (Figure R.14). These data strongly indicated the 
potential role of SOX17 downregulation in cholangiocarcinogenesis and 
supported the study of this transcription factor in the etiopathogenesis of CCA. 
A  
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Figure R.14. Relative SOX17 expression in NHC and CCA human cell lines. A) SOX17 
mRNA levels in NHC and CCA human cell lines (EGI1, TFK1, Witt). GADPH was used 
as housekeeping normalizing gene. B) Representative western blot of SOX17 protein 
in NHC and CCA human cell lines (EGI1, TFK1, Witt). β-actin was used as normalizing 
loading control. n=number of samples in each condition. 
 
R.7. Role of SOX17 in cholangiocarcinogenesis 
In order to evaluate the role of SOX17 on biliary cancer we overexpressed this 
transcription factor in CCA human cells (EGI1) by using lentiviral vectors 
encoding the SOX17 ORF. 
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R.7.1. Experimental overexpression of SOX17 in CCA human cells 
promotes its accumulation in the nucleus 
Lentiviral vectors containing SOX17 ORF (Lent-SOX17) under the regulation of 
the elongation factor 1α promoter were produced in collaboration with the group 
of Prof. José J. G. Marín (University of Salamanca, Salamanca, Spain), as 
described in the Materials and Methods section. First, we evaluated the 
multiplicity of infection (MOI) needed to overexpressed SOX17 in all CCA 
human cell lines in vitro. Thus, different MOIs (i.e. 1, 3, 5, 10 and 15) per cell 
were used. Western blot analysis for SOX17 revealed that 48 h after infection 
there is SOX17 overexpression, which is dependent on the MOI employed 
(Figure R.15).  
 
 
 
 
Figure R.15. Representative western blot showing SOX17 protein expression in CCA 
human cells infected with different MOIs of Lent-SOX17 compared to its basal levels in 
both NHC and CCA human cells. β-actin was used as a normalizing loading control. 
 
 
 
Results 
 
91 
 
Next, we performed immunofluorescence analysis to evaluate the proportion 
of CCA human cells showing SOX17 overexpression under the infection of 
different MOIs of Lent-SOX17 compared to CCA human cells infected with a 
Lent-control and to both NHC and CCA human cells under basal condition. 
Moreover, the location of SOX17 in the cells was investigated. In agreement 
with the western blot analysis, immunofluorescence also demonstrated that 
NHC possess higher basal levels of SOX17 protein than CCA human cells and 
this expression is mainly located in the nucleus of the cells but can also be 
found in the cytoplasm (Figure R.13). On the other hand, experimental 
overexpression of SOX17 in CCA human cells resulted in its accumulation in 
the nucleus, and the percentage of cell infection was dependent on the MOI 
employed (1, 3, or 5) compared to CCA human cells infected with Lent-control 
(MOI of 5) (Figure R.16). The MOIs of 3 and 5 resulted in the general infection 
(~100%) of CCA human cells and in the overexpression of SOX17 in the 
nucleus, whereas the MOI of 1 just infected a partial proportion (~40%) of the 
cells (Figure R.16). Based on these data, the MOI of 3 was used for further 
experiments of SOX17 overexpression as it is the minimal MOI by which all 
cells are infected and show non-saturating SOX17 overexpression.  
Results 
 
92 
 
 
 
Figure R.16. Representative immunofluorescence of SOX17 protein expression (red) in 
CCA human cells infected with different MOIs of Lent-SOX17 (1, 3 and 5) or Lent-
control (5), as well as in NHC and CCA human cells under basal conditions. Nuclei 
were stained with DAPI (blue).  
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R.7.2. Experimental overexpression of SOX17 in human CCA cells reduces 
their tumorigenic capacity in vivo 
We evaluated the role of SOX17 on the tumorigenic capacity of CCA human 
cells in vivo.  For this purpose, CCA human cells (105 cells) were infected 
subcutaneously into immunodeficient nude mice (Crl:NU-Foxn1nu). In 
particular, CCA human cells, previously infected with Lent-control or Lent-
SOX17 at a MOI of 3, were injected into the left or right flank of the back of 
eight immunodeficient mice, respectively (Figure R.17.A). Non-infected CCA 
human cells were injected in both flanks of an immunodeficient mouse as a 
control (data not shown). 
The tumor size monitoring was initiated one month after cell injection and 
was carried out every 3-4 days for an additional month before of the sacrifice 
of the animals. The tumors generated from CCA human cells infected with 
Lent-control showed continuous lineal growth overtime (Figure R.17.B), which 
was similar to the non-infected CCA human cells (data not shown). In 
contrast, CCA human cells infected with Lent-SOX17 showed smaller 
subcutaneous tumors, or even absence of tumors, compared to those 
generated CCA from human cells infected with Lent-control (Figure R.17.A-
C). 
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Figure R.17. Role of SOX17 in CCA tumor growth in immunodeficient mice. A) 
Representative images of an immunodeficient mouse before the sacrifice that received 
the injection of CCA human cells infected with Lent-control (left flank) and Lent-SOX17 
(right flank). B) Tumor volume measurement over time. C) Image comparing in pairs 
the tumors isolated after the sacrifice of the immunodeficient mice. 
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R.7.3. Experimental overexpression of SOX17 promotes apoptosis in CCA 
human cells but not in normal human cholangiocytes 
Since experimental overexpression of SOX17 in CCA human cells strongly 
reduced their tumorigenic capacity in vivo, we evaluated the molecular 
mechanism involved in this effect. First, we analyzed apoptosis in these cells. 
Our data indicated that experimental overexpression of SOX17 promotes cell 
death (i.e. apoptosis measured by Annexin V and Propidium Iodide) in CCA 
human cells in a MOI-dependent manner compared to cells infected with Lent-
control and non-infected cells (Figure R.18). The MOI previously chosen for the 
in vivo experiment (MOI=3) showed a ~45% of apoptosis (by Annexin V and 
Propidium Iodide) (Figure R.18).  
Since Lent-SOX17 increases the expression of SOX17 in CCA human cells 
beyond the basal expression levels of SOX17 in NHC, we evaluated the effect 
of the experimental overexpression of SOX17 on the NHC survival. Notably, in 
contrast to CCA human cells, experimental overexpression of SOX17 (MOIs 1, 
3 and 5) in NHC did not affect their survival (Figure R.19).  
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Figure R.18. Role of SOX17 in the survival of CCA human cells. Apoptosis was 
analyzed 48 h after CCA human cell infection with Lent-SOX17, Lent-control or in non-
infected cells by flow cytometry for A) Annexin V and B) Propidium Iodide. A and B 
show representative histograms and percentage of apoptosis in each assay. n=number 
of samples in each condition. 
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Figure R.19. Role of SOX17 experimental overexpression on NHC survival. Apoptosis 
was analyzed 48 h after NHC infection with Lent-SOX17, Lent-control or in non-
infected cells by flow cytometry for A) Annexin V and B) Propidium Iodide. A and B 
show representative histograms and percentage of apoptosis in each assay. n=number 
of samples in each condition. 
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Next, we studied the molecular mechanisms triggering the apoptotic effect of 
SOX17 in CCA human cells (using a MOI of 3) by analyzing the caspase-3 
activity. Caspase-3 activation may be the result of both mitochondrial-
dependent and/or mitochondrial-independent apoptosis. Increased caspase-3 
activity (measured by flow cytometry with the Phiphilux-G2D2 kit) was observed  
in CCA human cells infected with Lent-SOX17 for 48 h compared to cells 
infected with Lent-control or non-infected cells (Figure R.20).   
 
Figure R.20. Role of SOX17 in the caspase-3 activity of CCA human cells. Caspase-3 
activity was measured by flow cytometry (Phiphilux-G2D2 assay) in CCA human cells 
48 h after infection with Lent-SOX17, Lent-control or in non-infected cells. 
Representative histogram and percentage of caspase-3 activity in each assay. 
n=number of samples in each condition. 
 
The apoptotic process may be promoted by the activation of different 
intracellular signaling pathways. Here, we evaluated the relevant pro-apoptotic 
JNK/p53 signaling pathway. In particular, the c-Jun N-terminal protein kinase 
(JNK) activates by phosphorylation the activity of the pro-apoptotic transcription 
factors c-Jun [223] and p53 [224], among others [225]. Our data showed that 
experimental overexpression of SOX17 in CCA human cells increased the 
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phosphorylation of both JNK and p53 compared to cells infected with Lent-
control or non-infected (Figure R.21).  
 
Figure R.21. Representative western blots of the expression and phosphorylation of the 
pro-apoptotic proteins JNK and p53 in CCA human cells infected for 48 h with Lent-
SOX17, Lent-control or non-infected. β-actin was used as a normalizing loading 
control. 
 
Since apoptosis may be the result of increased oxidative stress in the cell 
[226-228], we measured the levels of reactive oxygen species (ROS) in CCA 
human cells by using the CellROX assay kit based on the detection of ROS 
formation by flow cytometry. Experimental overexpression of SOX17 in CCA 
Results 
 
100 
 
human cells with Lent-SOX17 for 48 h increased the ROS levels compared to 
cells infected with Lent-control or non-infected cells (Figure R.22). 
 
Figure R.22. Role of SOX17 in the oxidative stress CCA of human cells. ROS levels 
were analyzed by flow cytometry (CellROX Deep Red assay) in CCA human cells 
infected for 48 h with Lent-SOX17, Lent-control and non-infected. n=number of 
samples in each condition. 
 
R.7.4. Experimental overexpression of SOX17 in CCA human  cells inhibits 
the Wnt3a-dependent proliferation 
The role of SOX17 was also studied on the proliferation of those CCA human 
cells that did not enter in apoptosis. In particular, we evaluated the pro-mitotic 
and pro-tumorigenic Wnt/β-catenin pathway, which participates in 
cholangiocarcinogenesis [229]. Our data showed that Wnt3a ligand promotes 
the proliferation of non-infected CCA human cells in a dose-dependent manner 
(Figure R.23.A). Interestingly, the Wnt3a (400ng/mL)-dependent proliferation 
was inhibited in CCA human cells infected with Lent-SOX17 compared to cells 
infected with Lent-control and non-infected cells (Figure R.23.B). 
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Figure R.23. Role of SOX17 in the Wnt3a-dependent proliferation of CCA human cells. 
A) Wnt3a ligand promotes the proliferation of CCA human cells in a dose-dependent 
manner. B) Wnt3a (400 ng/ml)-dependent proliferation is inhibited in CCA human cells 
infected with Lent-SOX17 compared to cells infected with Lent-control or non-infected 
cells.  
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In addition, we evaluated the expression and phosphorylation levels of β-
catenin, which is a key effector in the Wnt signaling pathway. Different β-catenin 
residues may be phosphorylated determining its biological consequences. 
Thus, thr41/ser45 phosphorylation promotes a characteristic nuclear activation 
of β-catenin [122]. In contrast, phosphorylation of ser33/37/thr41 residues 
mediates the ubiquitin/proteasome-dependent degradation of β-catenin [230]. 
Our data showed that experimental overexpression of SOX17 in CCA human 
cells with Lent-SOX17 increased the ser33/37/thr41 phosphorylation of β-
catenin compared to cells infected with Lent-control or non-infected cells (Figure 
R.24). These data indicated that SOX17 may inhibit the Wnt/β-catenin-
dependent proliferation in CCA human cells by promoting the degradation of β-
catenin. 
                 
 
Figure R.24. Role of SOX17 in β-catenin (S33/37/T41) phospholylation. Representative 
western blots of p-β-catenin (S33/37/T41)/total β-catenin expression in CCA human 
cells infected with Lent-SOX17, Lent-control or non-infected cells. β-actin was used as 
normalizing loading control. 
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R.7.5. Experimental overexpression of SOX17 in CCA human cells inhibits 
cell migration 
We also evaluated the role of SOX17 in cell migration. Thus, cell migration was 
determined by the scratch method using non-infected, Lent-control or Lent-
SOX17 infected CCA human cells. Our data revealed that SOX17 
overexpression diminished CCA human cell migration in comparison with non-
infected or Lent-control infected CCA human cells (Figure R.25). 
A 
 
 
B 
 
Figure R.25. A) Representative microscopic images of the scratch-migration assay at 0 
and 24 h timepoints in CCA human cells infected with Lent-SOX17, Lent-control or 
non-infected cells. B) Relative area ratio 24 h after the scratch of the migrated CCA 
human cells infected with Lent-SOX17, Lent-control or non-infected cells. n=number of 
samples in each condition. 
 
R.7.6. Experimental overexpression of SOX17 in CCA human cells 
increases the expression of biliary markers of differentiation 
The role of SOX17 was studied on the expression of biliary epithelial 
markers of differentiation in those CCA human cells that did not enter in 
apoptosis. Thus, overexpression of SOX17 in CCA human cells increased the 
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mRNA levels of CK7, FN [231] and zonula occludins (ZO-1) [232] compared to 
cells infected with Lent-control or non-infected cells (Figure R.26). On the other 
hand, overexpression of SOX17 in CCA human cells downregulated the mRNA 
levels of the mesenchymal marker S100A4 [233, 234], which becomes 
upregulated in cholangiocarcinogenesis during the EMT process, compared to 
cells infected with Lent-control or non-infected cells (Figure R.26). 
 
Figure R.26. Relative mRNA expression of biliary (CK7, FN and ZO-1) and 
mesenchymal (S100A4) markers in CCA human cells with SOX17 overexpression 
compared with Lent-control infected and non-infected cells. GADPH was used as 
housekeeping normalizing gene. n=number of samples in each condition. 
 
R.7.7. Experimental overexpression of SOX17 in CCA human cells 
normalizes their diminished primary cilium length 
The primary cilium is a sensory organelle key for cholangiocyte biology but also 
involved in the pathogenesis of different cholangiopathies like CCA [11, 115, 
235]. In this regard, CCA human cells show  morphological and functional ciliary 
abnormalities characterized by shorter or even absent primary cilia due to 
HDAC6 overexpression that de-acetylates ciliary α-tubulin [115]. Here, we 
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evaluated in collaboration with the group of Dr. Sergio Gradilone (Hormel 
Institute, University of Minnesota, Austin, MN, USA) the role of SOX17 in the 
primary cilium length of CCA human cells. Experimental overexpression of 
SOX17 in those CCA human cells that did not enter apoptosis showed after 7 
days of confluence longer cilia than to those cells infected with Lent-control or 
non-infected cells (Figure R.27); this event was associated with decreased 
HDAC6 mRNA levels (Figure R.28). 
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Figure R.27. A) Representative confocal fluorescence microscopy images of primary 
cilia stained with acetylated α-tubulin (axoneme: red) and γ-tubulin (centrioles that form 
from the basal body of the cilium: green). Nuclei were stained with DAPI. B) Relative 
primary cilium length (μm) quantified by acetylated α-tubulin immunofluorescence 
staining. n=number of samples in each condition. 
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Figure R.28. Relative HDAC6 mRNA levels in CCA human cells infected with Lent-
SOX17, Lent-control or non-infected. GADPH was used as housekeeping normalizing 
gene. n=number of samples in each condition.  
 
R.8. Gene expression analysis by “mRNA microarrays” 
R.8.1. Samples 
For the “mRNA microarrays”, NHC both non-infected and infected, with Lent-
shRNA-control or Lent-shRNA-SOX17, were used. Infected cells were selected 
with puromycin for one week and then the RNA was isolated from the cells. On 
the other hand, CCA human cells (EGI1) infected with Lent-control, Lent-SOX17 
or non-infected were used and the RNA isolated after 6 h of infection. All these 
conditions are summarized as follows: 
a) non-infected NHC (NHC) 
b) NHC infected with Lent-shRNA-Control (N_shCtrl) 
c) NHC infected with Lent-shRNA-shSOX17 (N_shSOX17)  
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d) non-infected CCA (CCA)  
e) CCA infected with Lent-Control (C_Ctrl)  
 f) CCA infected with Lent-SOX17 (C_SOX17) 
The mRNA expression profiles were determined by using the 
Illumina_human_v6.2 microarray. The total mRNA was isolated by using the 
miRNeasy Micro kit (Qiagen) following the manufacturer’s instructions, as was 
described in Materials and Methods section M.13.1.  
 
R.8.2. Volvanoplots, heatmaps and gene functions 
Four different comparisons were carried out in order to determine the differential 
mRNA expression profile between NHC and CCA human cells (EGI) after the 
experimental modulation of SOX17 expression levels: 
i) “N_shSOX17” vs “NHC and N_shCtrl”: this condition determines the 
mRNA expression changes induced by knocking-down SOX17 in NHC 
compared to those genes similarly expressed between “non-infected 
NHC” and “NHC infected with Lent-shRNA-control”. 
ii) “N_shSox17 and CCA” vs “NHC and N_shCtrl”: this condition 
determines the mRNA expression changes induced by knocking-down 
SOX17 in NHC that are similar to CCA human cells (EGI1) but different 
to both “non-infected NHC” and “NHC infected with Lent-shRNA-control”. 
iii) “C_SOX17” vs “CCA and C_Ctrl”: this condition determines the mRNA 
expression changes induced by overexpressing SOX17 in CCA human 
cells (EGI1) compared to those genes similarly expressed between “non-
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infected CCA human cells (EGI1)” and “CCA human cells (EGI1) infected 
with Lent-control”. 
iv) “C_SOX17 and NHC” vs “CCA and C_Ctrl”: this condition determines 
the mRNA expression changes induced by overexpressing SOX17 in 
CCA human cells (EGI1) that are similar to NHC but different to those 
genes similarly expressed between “non-infected CCA human cells 
(EGI1)” and “CCA human cells (EGI1) infected with Lent-control”.  
 
R.8.2.1. Comparison #1: “N_shSOX17” vs “NHC and N_shCtrl” 
A volcanoplot analysis was performed to compare the gene expression (mRNA) 
profile between “N_shSOX17” and “NHC and N_shCtrl” groups (Figure R.29). 
Thus, the expression of those genes differentially expressed between “NHC 
cells under SOX17 downregulation” and “NHC controls (NHC and NHC Lent-
shRNA-control)” cells were compared. 
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Figure R.29. Volcanoplot analysis comparing the mRNA levels “NHC Lent-shRNA-
SOX17” cells against “NHC and NHC Lent-shRNA control” cells. Dots represent the 
expression of each particular gene. Blue dots represent genes downregulated (>-1.5-
fold change; p value <0.05) and red dots represent genes overexpressed (>+1.5-fold 
change; p value <0.05). Statistical variables: Log2 (Fold change >+/- 1.5) and Log10 (p 
value <0.05).  
 
 
Additionally, heatmaps showing the semi-quantitative expression of those 
genes differentially expressed (>+/<-1.5-fold change and p value <0.05) were 
generated (Figure R.30).  
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Figure R.30. Heatmaps showing those genes found upregulated (top) or 
downregulated (bottom) in “NHC Lent-shRNA-SOX17” cells compared to “NHC and 
NHC Lent-shRNA-Control” cells.  
 
The functional analysis of the dysregulated genes revealed that they 
participate in processes of cell migration, proliferation and survival (Figure 
R.31). Thus, experimental downregulation of SOX17 in NHC resulted in 
decreased expression of genes that inhibit cell migration/invasion [i.e CD24 
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[236, 237], MPZL2 (also known as EVA1) [238] and TM4SF4 [239]] and 
proliferation (i.e. IGFBP3 [240]). On the other hand, these results were 
associated with overexpression of genes that promote tumorigenesis [i.e. IFI27 
[241], IFI6 (also known as G1P3) [242], IFIT1 [243] and KIAA1199 [244, 245]] 
by regulating cell proliferation, migration and drug resistance. These data 
support the concept that SOX17 is a key regulator of NHC differentiation and its 
lack may promote tumorigenesis. 
           
          
 
Figure R.31. Clustering by cellular function of those genes found upregulated (top) or 
downregulated (bottom) in “NHC Lent-shRNA-SOX17” cells compared to “NHC and 
NHC Lent-shRNA-control” cells. Gene information collected from Pubmed, Uniprot or 
Genecards. 
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R.8.2.2. Comparison #2: “N_shSOX17 and CCA” vs “NHC and N_shCtrl” 
A volcanoplot analysis was performed to compare the gene expression (mRNA) 
profile between “N_shSOX17 and CCA” and “NHC and N_shCtrl” groups 
(Figure R.32). Thus, the expression of those genes similarly expressed between 
“NHC cells under SOX17 downregulation” and “CCA human cells (EGI1)” were 
compared with the NHC controls, “NHC and NHC Lent-shRNA-control” cells. 
 
 
 
 
 
Figure R.32. Volcanoplot analysis comparing the mRNA levels between “NHC Lent-
shRNA-SOX17 cells and CCA human cells (EGI1)” against “NHC and NHC Lent-
shRNA-Control” cells. Dots represent the expression of each particular gene. Blue dots 
represent genes downregulated (>-1.5-fold change; p value <0.05) and red dots 
represent genes overexpressed (>+1.5-fold change; p value <0.05).  Statistical 
variables: Log2 (Fold change >+/- 1.5) and Log10 (p value <0.05).  
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Additionally, heatmaps showing the semi-quantitative expression of those 
genes differentially expressed (>+/<-1.5-fold change and p value <0.05) were 
generated (Figure R.33).  
 
 
 
Figure R.34. Heatmaps showing those genes found upregulated (top) or 
downregulated (bottom) in “NHC Lent-shRNA-SOX17 cells and CCA human cells 
(EGI1)” compared to “NHC and NHC Lent-shRNA-Control” cells.  
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The functional analysis of the dysregulated genes revealed that they 
participate in processes of cell proliferation, migration and survival (Figure 
R.34). Those genes found downregulated in both “NHC Lent-shRNA-SOX17 
cells” and “CCA human cells (EGI1)” are negative regulators of carcinogenesis; 
thus, they are involved in the inhibition of cell migration and invasion (i.e. 
IFNGR1 [246], MPZL2 [238], RARRES1 [247], RYBP [248], SERPINA1 [249], 
STX12 [250]), tumor suppression (i.e.DCBLD2 [251], MPZL2 [238], RYBP 
[252]), inhibition of proliferation (i.e. DCBLD2 [253], IGFBP3 [240], RARRES1 
[247], RYBP [252]), stimulation of apoptosis (IFNGR1 [246], RYBP [248]), and 
chemosensitivity [i.e. MPZL2 [238], RARRES1 [254], RYBP [248]). On the other 
hand, the genes found upregulated in these conditions may play a role (based 
on gene ontology program) in the ubiquitin-proteasome pathway (i.e. DNAJA1 
[255]), in degradation of protein-aggregates (i.e. HSPA1B [256]) and in the 
promotion of proliferation and tumorigenesis (i.e. IFI27 [241]). 
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Figure R.34. Clustering by cellular function of those genes found upregulated (top) or 
downregulated (bottom) in both “NHC Lent-shRNA-SOX17 cells and CCA human cells 
(EGI1)” compared to “NHC and NHC Lent-shRNA-control” cells. Gene information 
collected from Pubmed, Uniprot or Genecards. 
 
R.8.2.3. Comparison #3: “C_SOX17” vs “CCA and C_Ctrl” 
A volcanoplot analysis was performed in order to compare the gene expression 
(mRNA) profile between “C_SOX17” and “CCA and C_Ctrl” groups (Figure 
R.35). Thus, the expression of those genes differentially expressed between 
“CCA Lent-SOX17” and its controls “CCA human cells (EGI1) and CCA Lent-
control cells” were compared. 
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Figure R.35. Volcanoplot analysis comparing the mRNA levels betweem “CCA Lent-
SOX17” and “CCA human cells (EGI1) and CCA Lent-control cells”. Dots represent the 
expression of each particular gene. Blue dots represent genes downregulated (>-1.5-
fold change; p value <0.05) and red dots represent genes overexpressed (>+1.5-fold 
change; p value <0.05). Statistical variables: Log2 (Fold change >+/- 1.5) and Log10 (p 
value <0.05).  
  
 
 
Additionally, heatmaps showing the semi-quantitative expression of those 
genes differentially expressed (>+/-1.5-fold change and p value <0.05) were 
generated (Figure R.36).  
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Figure R.36. Heatmaps showing those genes found upregulated (top) or 
downregulated (bottom) in “CCA Lent-SOX17” cells compared to “CCA human cells 
(EGI1) and CCA Lent-control cells”.   
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Experimental overexpression of SOX17 in CCA human cells (EGI1) only 
induced the upregulation of ATP1B1 (in addition to SOX17), which has been 
reported to promote FGF2 secretion [257] that participates in biliary cell 
differentiation [258]. On the other hand, experimental overexpression of SOX17 
in CCA human cells (EGI1) resulted in decreased expression of multiple genes 
(Figure R.37). Some of these downregulated genes have pro-tumorigenic 
capacity; thus, they may promote cell proliferation (i.e. CREB1 [259], KCNH6 
[260], MGC16703, POFUT1 [261], CDKN2AIPNL, PDE4C [262], ZMAT3 [263]), 
invasion/migration (i.e. CDCP1 [264], CREB1 [265], KCNH6 [260], LRRFIP1 
[266], POFUT1 [267]), neoangiogenesis (i.e. KCNH6 [260]) and survival (i.e. 
ZMAT3 [263], XPNPEP3 [268], DUSP19 [269]). In addition, other genes found 
downregulated under SOX17 overexpression in CCA human cells (EGI1) are 
involved in cell differentiation (EID2B, POFUT1 [267]), development (C14orf85, 
also known as ITPK1 antisense RNA 1 [270]), homeostasis of mitochondria 
(PNPT1 [271], XPNPEP3 [268]), endoplasmic reticulum (RN7SL1 [272]), 
ribosome biogenesis (BMS1P5, DDX51 [273], RRP7B), DNA damage response 
and/or genomic stability (C9orf80, also named INTS3 [274], CDKN2AIPNL), 
calcium release (ITPRIPL2), transporter activity (HIATL2) and chemoresistance 
(CDCP1 [275]). 
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Figure R.37. Clustering by cellular function of those genes found downregulated in 
“CCA Lent-SOX17” compared to “CCA human cells (EGI1) and CCA Lent-control 
cells”. Gene information collected from Pubmed, Uniprot or Genecards. 
 
 
 
 
 
 
 
R.8.2.4. Comparison #4: “C_SOX17 and NHC” vs “CCA and C_Ctrl” 
A volcanoplot analysis was performed to compare the gene expression (mRNA) 
profile between “C_SOX17 and NHC” and “CCA and C_Ctrl” groups (Figure 
R.38). Thus, the expression of those genes similarly expressed between “CCA 
Lent-SOX17 and NHC” cells were compared with “ CCA human cells (EGI1) 
and CCA Lent-control cells”. 
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Figure R.38. Volcanoplot analysis comparing the mRNA levels between “CCA Lent-
SOX17 and NHC” cells and its controls “CCA human cells (EGI1) and CCA Lent-
control cells”. Dots represent the expression of each particular gene. Blue dots 
represent genes downregulated (>-1.5-fold change; p value <0.05) and red dots 
represent genes overexpressed (>+1.5-fold change; p value <0.05).  Statistical 
variables: Log2 (Fold change >+/- 1.5) and Log10 (p value <0.05).  
 
 
This last comparison determined the similarities between NHC cells and CCA 
Lent-SOX17 compared to controls, CCA human cells (EGI1) and CCA Lent-
control cells. Two genes appeared to be downregulated in “C_SOX17 and 
NHC” group, CREB1 [276] and LRRFIP1 [277], which are key players in tumor 
proliferation and invasion, respectively. 
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R.9. Mechanisms of regulation of SOX17 expression in normal human 
cholangiocytes and CCA human cells 
R.9.1. DNMT1 and 3B are overexpressed in CCA human cells compared to 
normal human cholangiocytes in culture 
Epigenetic alterations have been described in CCA, including hypermethylation 
of gene promoters [107, 278]. Methylation is carried out by DNMT enzymes 
(DNMT1, 3a and 3b), which have the function of transferring a methyl group 
onto DNA cytosines [279]. Some of those enzymes, DNMT1 and DNMT3b, 
have been identified to be overexpressed in CCA [280]. DNMT1 seems to be 
the key constitutive player in DNA methylation, whilst DNMT3b has been 
reported to support the function of DNMT1 [280]. However, no data has 
previously been published related to DNMT3a and CCA. We analyzed the 
expression of DNMT1, 3a and 3b in three diverse CCA human cell lines 
compared to NHC. Our data showed that both DNMT1 and DNMT3b are 
overexpressed in all three CCA human cell lines compared to NHC (Figure 
R.39). 
 
Figure R.39. Relative DNMT1, DNMT3a and DNMT3b mRNA levels in three CCA 
human cell lines (EGI1, TFK1, Witt) compared to NHC. GADPH was used as 
housekeeping normalizing gene. n=number of samples in each condition. 
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R.9.2. Both TGFβ1 and Wnt3a decrease SOX17 mRNA expression in 
normal human cholangiocytes in culture 
We studied the molecular mechanisms involved in the regulation of SOX17 
expression in NHC. In particular, we evaluated the role of two ligands found 
highly present in the inflammatory microenvironment of human CCAs such as 
TGFβ1 and Wnt3a. TGFβ1 promotes inflammation [281, 282] and/or 
fibrogenesis [283], whereas Wnt3a stimulates proliferation through the Wnt/β-
catenin pathway [284, 285]. Our data showed that treatment of NHC with either 
TGFβ1 (5 ng/mL) or Wnt3a (100 ng/mL) for 48 h reduced SOX17 mRNA 
expression compared to non-treated cells (Figure R.40).  
The promoter of SOX17 gene was reported hypermethylated in CCA human 
tissues [106]. Therefore, we evaluated if the downregulation of SOX17 
expression induced by either TGFβ1 and/or Wnt3a was dependent of DNMT 
activity. For this purpose, we used decitabine (5’-aza-2’-deoxycytidine), an 
inhibitor of DNMT activity that particularly inhibits DNMT1, main constitutive 
DNMT in most cells including cholangiocytes [286] and the DNMT observed to 
be most significantly overexpressed in CCA (Figure R.39). Thus, NHC in the 
presence or absence of TGFβ1 or Wnt3a were treated with decitabine for 48 h. 
Our data showed that the presence of decitabine in the culture medium 
prevented the downregulation of SOX17 expression mediated by either TGFβ1 
or Wnt3a in NHC (Figure R.40). These data indicate that TGFβ1 and Wnt3a 
inhibit SOX17 expression in NHC through a DNMT-dependent methylation 
mechanism. 
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Figure R.40. Relative SOX17 mRNA expression in NHC in the presence or absence of 
TGFβ1 (5 ng/mL) or Wnt3a (100 ng/mL) for 48 h. GADPH was used as housekeeping 
normalizing gene. n=number of samples in each condition. 
 
R.9.3. Epigenetic regulation of SOX17 expression in CCA human cells 
Our previous data showed that TGFβ1 and Wnt3a both inhibit SOX17 
expression in NHC by a DNMT-dependent mechanism. These data together 
with the hypermethylation of SOX17 promoter reported in CCA human tissues 
[106] prompted us to study the role of both DNMT1 and inhibitors of DNMT 
activity on the regulation of SOX17 expression in CCA human cells. Our data 
showed that the transfection of three different  CCA human cell lines (i.e. EGI1, 
TFK1, and Witt) with siRNAs against DNMT1 decreased the mRNA expression 
of DNMT1 compared to control groups (i.e. non transfected cells or transfected 
with siRNAs control), and this event was associated with increased expression 
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of SOX17 mRNA in all three CCA human cell lines (Figure R.41). Moreover, 
incubation of CCA human cells (i.e. EGI1, TFK1, and Witt) with decitabine 
increased the mRNA and protein expression levels of SOX17 in all three CCA 
human cell lines (Figure R.42). 
 
 
 
 
Figure R.41. Relative DNMT1 and SOX17 mRNA expression in three CCA human cell 
lines (EGI1, TFK1 and Witt) in the presence or absence of siRNA-control or siRNA-
DNMT1 for 48 h. GADPH was used as housekeeping gene. n=number of samples in 
each condition. 
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Figure R.42. Role of DNMT activity in the regulation of SOX17 expression in CCA 
human cells. A) Relative SOX17 mRNA expression in three CCA human cell lines 
(EGI1, TFK1 and Witt) in the presence or absence of decitabine (1 µM) for 48 h. 
GADPH was used as housekeeping normalizing gene. B) Representative western blot 
of SOX17 protein expression in three CCA human cell lines (EGI1, TFK1 and witt) in 
the presence or absence of decitabine (1 µM). β-actin was used as normalizing loading 
control. n=number of samples in each condition. 
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R.10. Schematic summary of the results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  
  

  
 
 
 
 
 
 
 
 
 
 
V. DISCUSSION 
 
 
 
 
 
 
 
  
 
 
 
 
Discussion 
 
 
 
131 
Cholangiocarcinoma (CCA) is a heterogeneous group of cancers with features 
of biliary tract differentiation. Incidence is increasing worldwide and already 
represents the second most common primary liver tumor and accounts for up to 
~3% of all gastrointestinal cancers [41, 287]. CCAs are anatomically classified 
according to their localization in intrahepatic (iCCA), perihilar (pCCA) and distal 
(dCCA) [41, 287]. Their etiopathogenesis remains obscure; some risk factors 
such as viral hepatitis B and C, primary sclerosing cholangitis, liver fluke 
infection, hepatolithiasis, biliary malformations and congenital diseases have 
been described, but CCAs usually do not show any of them associated [41]. 
CCAs are very lethal because of their aggressiveness, late diagnosis and high 
chemoresistancence. They are generally diagnosed in advanced stages, when 
the disease is widespread. Thus, the 5-years survival rate after diagnosis is 
~15% [288]. Currently, surgical approaches and liver transplantation are 
considered the only potential curative options, but are only indicated in a small 
proportion of patients who follow strict criteria and chances of recurrency are 
high. Other strategies like radiotherapy or chemotherapy are considered mainly 
palliative [8]. Therefore, there is an urgent need to look for new curative 
therapeutic options. In order to determine new potential targets for therapy it is 
mandatory to understand in detail the molecular mechanisms triggering the 
pathogenesis of this cancer.  
Different genetic and epigenetic alterations have been described in CCA. 
Hypermethylation of the genome was recently reported in human CCA tissues 
compared to normal human livers [106]. Among other genes, the promoter of 
SOX17 was found hypermethylated [106]. SOX17 is a transcription factor 
member of the SOX family genes that is essential for the development of 
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definitive endoderm in mammals [187]. Thus, haploinsufficiency of SOX17 in 
heterozygote mice embryos results in biliary atresia, acute embryonic hepatitis 
and perinatal death [189]. Therefore, SOX17 has been considered a key player 
in the embrionary development of the biliary tree [188]. However, the particular 
role of SOX17 in the differentiation of cholangiocytes remains unknown. Here, 
we evaluated the role of SOX17 in the regulation of the phenotype of normal 
human cholangiocytes (NHC) by using two different approaches; i) experimental 
differentiation of human iPSCs into NHC, and ii) dedifferentiation of NHC in 
culture. 
It was recently reported that human iPSCs can be differentiated into NHC. 
Isolated human myofibroblasts transfected with vectors expressing OCT4, 
SOX2, KLF4 and cMYC induced stem cell pluripotency, and a stepwise 
differentiation using Activin A, Wnt3a, FGF2, BMP4, SHH, JAG-1 and TGFβ, 
leads to iPSC-derived cholangiocytes (as previously described in Materials and 
Methods, section M.2.1) [207]. These cells show typical cholangiocyte features 
such as expression of CK7, CK19, PKD2, CFTR, and AE2, and also present the 
primary cilium [207]. Following this approach, we found that SOX17 protein 
expression is highly induced in the last step of the differentiation process of 
human iPSCs into NHC, i.e. in the differentiation of hepatic progenitor cells into 
mature cholangiocytes. This event was also associated with increased 
expression of CK7 and CK19. In order to determine the regulatory role of 
SOX17 in the differentiation of hepatic progenitor cells into mature NHC, we 
knocked-down SOX17 in different steps of the differentiation process of iPSCs 
into cholangiocytes by using Lent-shRNA-SOX17. Our data indicated that 
experimental downregulation of SOX17 protein during the differentiation of iPSC 
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into cholangiocytes decreases the protein levels of CK7 and CK9. Since the 
induction of SOX17 protein expression in the last step of the experimenral 
differentiation process is very high, the use of Lent-shRNA-SOX17 only partially 
(but significantly) decreases the expression of SOX17 and the resultant CK7 
and CK19 proteins.  
On the other hand, we evaluated the role of SOX17 in the regulation of the 
biliary phenotype of NHC in culture. Over cell passages in vitro, NHC 
progressively lose the expression of biliary and epithelial markers (such as CK7, 
CK19, and E-cadherin) and enter in senescence, which is characterized by: a) 
ovexpression of the senescent marker p21, b) β-galactosidase hyperactivity 
[220], c) downregulation of CDK4 expression [289] and d) upregulation of 
p16INK4A expression (another senescence marker that inhibits CDK4 and thus 
induces cell cycle arrest [219, 289]. Notably, we found that SOX17 expression 
progressively decreases over culture-passages of NHC. In order to define the 
role of SOX17 in the dedifferentiation of NHC over culture-passages, we 
infected low passage cells with Lent-shRNA-SOX17 and then evaluated the 
expression of biliary epithelial markers. Our data revealed that experimental 
downregulation of SOX17 in low passage NHC resulted in downregulation of 
CK7 and CK19 expression; however, the expression of SOX17 did not affect 
senescence, since the expression of senescence markers, such as p16INK4A 
and p21, and the activity of β-galactosidase were unaffected by SOX17 
downregulation.  
Since SOX17 was suggested as a negative regulator of the Wnt/β-catenin 
pathway, we evaluated its role in the Wnt/β-catenin proliferation of NHC. Our 
data showed that the Wnt3a ligand does not modify the proliferation rate of 
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NHC. However, experimental downregulation of SOX17 expression in low 
passage NHC promotes a Wnt3a-dependent proliferation; this event was 
associated with decreased expression levels of SFRP1, a Wnt ligand inhibitor. 
This data indicated that downregulation of SOX17 expression in NHC promotes 
their transformation into a pro-mitotic state. This conclusion was supported by 
the data acquired from the mRNA array analysis, which showed a decreased 
mRNA expression of inhibitors of proliferation (IGFBP3 [240], DCBLD2 [251], 
RARRES1 [247], RYBP [252]) after experimental SOX17 knocking-down in 
NHC. Moreover, the expression of genes that pomote tumorigenesis (IFI27 
[241], IFI6 [242], IFIT1 [243], KIAA1199 [244, 245]) and are implicated in protein 
degradation (DNAJA1 [255], HSPA1B [256]) appeared to be overexpressed, 
and inhibitors of  cell migration/invasion downregulated (CD24 [236, 237], 
MPZL2 [238], IFNGR1 [246], SERPINA1 [249], STX12 [250]) in NHC under 
SOX17 experimental downregulation. 
The data resulting from these two experimental models (i.e. differentiation of 
iPSCs into mature cholangiocytes and NHC in culture) strongly indicate that 
SOX17 is a marker of biliary tract differentiation that also plays a key role in the 
regulation and maintenance of the cholangiocyte phenotype. These data are 
consistent with the aforementioned previous reports showing that SOX17 
heterozygote mice show biliary abnormalities and perinatal death [16, 187, 189].  
Based on these results, and on the recently reported data showing that the 
SOX17 promoter is found hypermethylated in CCA human tissues, we 
evaluated the expression of SOX17 in both CCA human tissue and cell lines 
(i.e. EGI1, TFK1 and Witt). Since normal human liver biopsies are mainly 
composed by hepatocytes, which show very low expression of SOX17 [221] the 
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SOX17 mRNA levels in CCA human tissue were compared to both low 
passages of NHC and normal gallbladder human tissue (which is highly 
composed by cholangiocytes) [222]. Our data revealed that SOX17 mRNA 
expression is downregulated in CCA human tissue compared to both primary 
culture of NHC and normal human gallbladder tissue. In addition, SOX17 mRNA 
expression was found strongly reduced in all three CCA human cell lines 
compared to NHC in culture. The immunofluorescence (IF) studies in human 
liver tissue showed that CK19-positive cells (i.e. cholangiocytes) possess high 
expression of SOX17, which is localized mainly perinuclearly in the bile duct 
epithelium cells; on the other hand, almost undetectable SOX17 expression was 
found by IF in CCA human tissue. All these data indicate that downregulation of 
SOX17 expression is a general and specific event occurring in CCAs and that 
could play a key role in the etiopathogenesis of this disease. These data are 
consistent with recent studies showing hypermethylation of SOX17 promoter in 
CCA human tissue [106].  
In order to explore the potential role of SOX17 in the pathogenesis of CCA, 
we generated lentiviruses overexpressing SOX17 (Lent-SOX17). These viruses 
were used to infect the CCA human cells (i.e. EGI1), which show very low 
(mRNA and protein) SOX17 expression and high tumorigenic capacity. First, we 
infected these tumoral cells with different MOIs (i.e. 1, 3, 5, 10, 15). Western 
blot analysis showed a MOI-dependent overexpression of SOX17 in CCA 
human cells, reaching to a plateau at a MOI of 5. Then, we analyzed by IF the 
percentage of cells infected with different MOIs of Lent-SOX17, and found that 
the MOI of 3 is the minimum needed to have ~100% of cell infection. The 
SOX17 overexpression was mainly found in the nucleous of the cells. 
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Therefore, we decided to use a MOI of 3 for further experiments, since it is the 
minimum amount needed to induce SOX17 overexpression in all the CCA 
human cells. Then, the role of SOX17 was evaluated on the tumorigenic 
capacity of CCA human cells in vivo. For this purpose, CCA human cells 
infected with Lent-SOX17, Lent-control or non-infected were subcutaneously 
injected in immunodeficient nude mice and the tumor generation and growth 
was monitored over 57 days. Experimenntal overexpression of SOX17 
markedly reduced the subcutaneous generation of tumors and their growth 
compared to the controls. These data indicated that SOX17 acts as a tumor 
suppressor in CCA human cells. The tumor suppressor capacity of SOX17 was 
previously indicated in gastrointestinal tumors such as HCC [198], colorectal 
cancer [202], gastric tumors [197] and esophageal cancer [290]. Whilst in HCC 
cells restoration of SOX17 inhibits colony formation and cell growth by blocking 
β-catenin/TCF-dependent transcription [198], in colorrectal cancer  SOX17 
inhibits tumorigenesis through upregulation of miR-371-5p, which ultimately 
downregulates SOX2 and Wnt/β-catenin signalling [202]. Furthermore, re-
expression of SOX17 in esophageal cancer cells causes reduced foci formation, 
xenograft growth and metastasis [290]. In a mouse model of gastric 
tumorigenesis, SOX17 also reduces colony formation and Wnt signaling activity 
[197]. 
Then, we studied in vitro the mechanisms by which SOX17 functions as a 
tumor suppressor in CCA. Different biological processes altered in 
cholangiocarcinogenesis such as survival, proliferation, migration and 
differentiation were evaluated. Our data showed that SOX17 overexpression in 
CCA cells induces apoptosis in a MOI-dependent manner. Since Lent-SOX17 
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upregulates SOX17 expression in CCA human cells beyond the normal basal 
level in NHC, we evaluated the potential toxicity of SOX17 overdose. Thus, we 
tested the effect of Lent-SOX17 in NHC. In contrast to CCA human cells, 
overexpression of SOX17 did not promote apoptosis in NHC in culture, even at 
high MOIs of Lent-SOX17. Notably, this differential effect of SOX17 
overexpression on the survival of CCA human cells vs NHC points out the 
potential therapeutic value of SOX17 regulation for the treatment of CCA human 
tumors.  
Next, we studied the molecular mechanisms by which SOX17 
overexpression promotes apoptosis in CCA cells. Since oxidative stress is 
considered a potential inducer of apoptosis [291], we evaluated the levels of 
ROS in CCA human cells. Our data demonstrated that CCA human cells 
overexpressing SOX17 presented higher ROS levels than non-infected or Lent-
control CCA cells, suggesting that increased oxidative stress may be a cause 
for the increased apoptosis observed in CCA human cells under SOX17 
overexpression. Then, we evaluated the caspase-3 activity, which promotes 
apoptosis [292]. Overexpression of SOX17 in CCA human cells increases the 
caspase-3 activity compared to the control conditions; moreover, this event was 
also associated with increased phosphorylation of the pro-apoptotic signaling 
pathways JNK [293, 294] and p53 [293, 295]. In aggreement with these results, 
the analysis of expression of the mRNA microarrays indicated that experimental 
overexpression of SOX17 in CCA human cells dysregulated the expression of 
key genes involved in mitochondrial homeostasis and apoptosis. Thus, SOX17 
decreased the expression of PNPT1 [a mitochondrial homeostasis keeper 
relevant in the mitochondrial RNA (mtRNA) import] [296], DUSP19 (an indirect 
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JNK inhibitor, also known as SKRP1) [269, 297, 298], ZMAT3 (an anti-apoptotic 
gene and a p53 inhibitor) [299] and XPNPEP3 (an anti-apoptotic gene, also 
known as APP3 [300], related to mitochondrial oxygen consumption) [301] in 
CCA human cells compared to the controls. 
SOX17 was previously reported as a potential inhibitor of the Wnt/β-catenin 
pathways in different cancers such as breast cancer, colorectal cancer, 
hepatocarcinoma or gastric cancer [198, 199, 202, 302]. Since this molecular 
pathway is very relevant in cholangiocarcinogenesis [130, 229, 303, 304] and 
Wnt ligands are highly present in the tumor microenvironment [129, 305, 306], 
we evaluated the activity of this pro-tumorigenic pathway in those CCA human 
cells that showed experimental overexpression of SOX17 but with levels not 
sufficient to induce apoptosis. First, we observed that the presence of the 
Wnt3a ligand promotes the proliferation of CCA human cells in a dose-
dependent manner. Of note, the Wnt3a-dependent proliferation was inhibited in 
CCA human cells under experimental overexpression of SOX17. SOX17 is 
known to inhibit the Wnt signaling by promoting the expression of the Wnt 
ligand inhibitor SFRP1 [203] and/or by inhibiting β-catenin expression and 
activity. The degradation of β-catenin is mediated by a protein complex that 
contains the Ser/Thr kinases glycogen synthase kinase 3 (GSK3), casein 
kinase 1 (CK1), the scaffolding protein Axin, the APC protein, the E3-ubiquitin 
ligase and the protein phosphatase 2A (PP2A). The specific phosphorylation of 
β-catenin determines its activation (ser37/thr41 or thr41/ser45) or 
inactivation/degradation (ser33/37/thr41) [122] by ubiquitination and head 
towards the proteasome [307]. Our data revealed that experimental 
overexpression of SOX17 in CCA human cells increased the levels of β-catenin 
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phosphorylated in residues ser33/37/thr41, indicating its 
inactivation/degradation. Furthermore, the analysis of expression of the mRNA 
microarrays indicated that experimental overexpression of SOX17 in CCA 
human cells also downregulated the expression of some genes implicated in 
cell cycle and proliferation, such as CREB1 [259], KCNH6 [260], MGC16703, 
POFUT1 [261], CDKN2AIPNL and PDE4C [262].  
Another important feature of CCA tumors is their ability to invade adjacent 
tissues and/or migrate to other regions of the human body.  Thus, we evaluated 
the invasion/migration acivity of those CCA human cells that showed 
experimental overexpression of SOX17 but with levels not sufficient to induce 
apoptosis. Our “cell scratching” in vitro data showed that experimental 
overexpression of SOX17 inhibited the invasion/migration capacity of CCA 
human cells compared to control conditions. These data were associated with 
downregulation of the pro-invasion/migration genes S100A4 [308-312] as well 
as CDCP1 [264], CREB1 [265], KCNH6 [260], LRRFIP1 [266], POFUT1 [267] 
(data obtained from the mRNA microarray). 
On the other hand, we evaluated the role of SOX17 regulating the biliary 
phenotype in those of CCA human cells that did not enter apoptosis. We found 
that experimental overexpression of SOX17 in CCA human cells stimulated the 
expression of the biliary marker CK7, and epithelial markers FN [231] and ZO-1 
[232], which loss or failure have been related to cancer progression [231, 232]. 
In this regard, functional differentiated cholangiocytes present a single primary 
cilium extending from the apical membrane [11, 235]. This antenna-like 
organelle functions as a mechano-, chemo- and osmo-sensor detecting 
extracellular changes in bile flow and composition and regulating the 
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cholangiocyte function [11, 14, 313]. The primary cilia itself functions as a 
structural checkpoint that blocks cell cycle [314], thus its loss or shortening 
induces proliferation in some cholangiopathies [315]. In particular, CCA human 
cells show loss or decreased primary cilium length compared to normal biliary 
epithelial cells; this event is dependent on HDAC6 [115] that deacetylates the 
scaffold α-tubulin protein of the cilium. Our data revealed that experimental 
overexpression of SOX17 in CCA human cells increased the length of the 
primary cilium compared to the control conditions, indicating improved cell 
polarity and differentiation, and this event was associated with downregulation 
of HDAC6 mRNA expression. In this regard, a recent report indicated that 
molecular or pharmacological downregulation of HDAC6 expression in CCA 
human cells induces the restoration of primary cilium length and reduces cell 
proliferation, anchorage independent growth and invasion in a ciliary dependent 
manner [115, 235]. Future studies should evaluate in detail the mechanisms by 
which SOX17 regulates the primary cilium length in CCA human cells, as well 
as determine if these longer cilia are functional and respond to mechano-, 
chemo- and osmo-stimuli; moreover, their role in the proliferation of CCA 
human cells should be investigated. 
Finally, we studied the molecular mechanisms triggering the downregulation 
of SOX17 expression in CCAs. For this purpose, we evaluated the role of two 
key molecules in cholangiocarcinogenesis such as TGFβ1 [282], a pro-
inflammatory and pro-fibrotic protein [316], and the pro-mitotic Wnt3a ligand 
[317, 318]. We focused our studies in these two ligands because previously 
published data indicated that the cancer-associated fibroblasts (CAFs) and the 
activated macrophages, which are part of the tumor microenvironment, release 
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TGFβ1 [319] and Wnt3a [129] ligands respectively, and activate diverse 
tumorigenic signaling pathways into the proximate cells transforming them into 
cancerous cells [129, 320] or inducing their proliferation [321, 322]. 
Interestingly, incubation of NHC in culture with either TGFβ1 or Wnt3a 
decreased the mRNA expression of SOX17, and this event was prevented by 
the presence of the demethylating agent decitabine (5-aza-2’-deoxycytidine), 
which inhibits DNMTs activity by a covalent binding to these enzymes [323]. 
These data indicate that molecules present in chronic inflammatory processes 
and in the tumor microenvironment are able to downregulate the expression of 
the biliary marker SOX17 via a DNA methylation-dependent mechanism. As 
mentioned above, hypermethylation of SOX17 promoter was reported in CCA 
human tissues compared to controls [106]. Here, we found that both CCA 
human cells and tissues are characterized by downregulation or absent 
expression of SOX17. In order to test if the downregulation of SOX17 
expression in CCA human cells is caused by epigenetic regulation, particularly 
hypermethylation of the SOX17 promoter, we evaluated the role of DNMTs in 
this process. First, we found that the expression of both DNMT1 (main 
constitutive DNA methyltransferase)[324] and DNMT3b is increased in CCA 
human cells compared to normal human cholangiocytes. Notably, experimental 
knock-down of DNMT1 expression in CCA cells with specific siRNAs resulted in 
the upregulation of SOX17 mRNA expression. In addition, the use of decitabine 
increased both SOX17 mRNA and protein levels in all three CCA human cell 
lines analyzed (i.e. EGI1, TFK1 and Witt). 
In summary, all these data strongly indicate that SOX17 is a key 
transcription factor that regulates the differentiation and maintainance of the 
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biliary phenotype. Therefore, SOX17 may be considered and used as a biliary 
epithelial marker. Downregulation of SOX17 expression in NHC may occur 
during chronic inflammatory processes by the action of molecules such as 
TGFβ1 and Wnt3a, among others, via methylation of SOX17 gene promoter. 
Downregulation of SOX17 expression is a general and specific event necessary 
for cholangiocarcinogenesis because it functions as tumor suppressor 
promoting apoptosis, inhibiting both the Wnt/β-catenin-dependent proliferation 
and cell invasion/migration, and restoring the expression of key biliary epithelial 
markers as well as the length of the primary cilium. The characteristic 
downregulation of SOX17 expression in CCA human cells might be considered 
a marker of diagnosis and bad prognosis, although future studies in long 
cohorts of patients are still necessary. 
Overall, therapeutic strategies aimed to normalize/increase the expression 
levels of SOX17 in CCA human tumors might be highly effective. In this regard, 
we are going to explore in future studies the use of gene therapy with adeno-
associated viruses overexpressing SOX17. In the aforementioned studies, we 
used lentiviruses as vectors to overexpress SOX17 because of their high 
infection efficiency (independently of cell status) and genome integration 
capacity. However, we are going to generate adenoviruses overexpressing 
SOX17 for in vivo studies, which show high tropism to liver cells. The use of 
adenoviruses in vivo is more appropriate and safe than lentiviruses, because 
the latter may cause gene sequence dysruptions when it integrates aleatorily 
into the host genome. We are going to generate adenoviruses that encode 
SOX17 ORF under the regulatory expression of a constitute promoter; our aim 
will be to evaluate the therapeutic value of the intravenous injection of these 
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viruses in an orthotopic mouse model of CCA recently settled up in our 
laboratory. The fact that experimental overexpression of SOX17 in NHC did not 
affect their survival and proliferation, minimizes the potential side effects in 
normal biliary cells. However, future studies must be carried out in order to 
determine the potential side effects associated to SOX17 overexpression in 
other cell types such as normal hepatocytes. In this regard, we are going to 
design adenoviruses in which SOX17 expression will be regulated under CK19-
promoter (pr-CK19) as a specific way to force selective SOX17 expression in 
CCA human cells. Moreover, we are also considering the option of using 
promoters of relevant pro-oncogenes in CCA to specifically express SOX17 in 
these malignant cholangiocytes. On the other hand, to increase the security and 
in agreement with the last gene-therapy advances, we will carry out similar in 
vivo assays using adeno-associated viruses (AAV) encoding SOX17. The 
increasing number of clinical trials using non-pathogenic parvovirus AAV for 
gene transfer makes these vectors the best candidates for next-generation 
gene-therapy [325, 326]. 
CCAs are very chemorresistant tumors. So, we are going to check if SOX17 
modulates the chemosensibility or chemoresistance of CCA human cells to the 
antitumoral drugs commonly used in CCA, such as gemcitabine, 5-FU or 
cisplatin. We are going to evaluate the effect of SOX17 in the modulation of the 
expression of several genes involved in the chemoresistance status of CCAs 
[327]. 
Moreover, the epigenetic regulation of SOX17 expression in CCAs with 
demethylating agents may be considered for future therapeutic approaches. In 
this regard, demethylating agents have been shown to improve CCA prognosis, 
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as it has been reported that decitabine inhibits CCA cell growth in vitro and in a 
mouse xenograft model [328]. Decitabine is a drug approved by the food and 
drug administration (FDA) for the treatment of human diseases such as 
myelodysplastic syndromes [329]. So, taking into account this information and 
the relevance of decitabine as inhibitor of the SOX17 promoter 
hypermethylation in CCA human cells, it is suggested as a good therapeutic 
drug to be considered in the clinic.   

  
 
 
  

  
 
 
 
 
 
 
 
 
 
VI. CONCLUSIONS 
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The key findings reported here indicate that SOX17 is a key regulator of the 
differentiation and maintenance of the biliary phenotype and acts as a tumor 
suppressor in CCA, being considered a potential therapeutic target. Our data 
indicate that: 
I. SOX17 regulates the differentiation of iPSC cells into cholangiocytes and 
is particularly expressed in last step of the differentiation process, i.e. 
from hepatic progenitor to induced differentiated cholangiocytes.  
II. SOX17 is highly constitutive expressed in well differentiated human 
cholangiocytes and, similarly to CK7 and CK19, may be considered a 
biliary marker.  
III. SOX17 regulates the expression of the biliary markers CK7 and CK19 in 
normal human cholangiocytes and does not affect cell senescence. 
IV. Experimental downregulation of SOX17 expression in normal human 
cholangiocytes promotes their Wnt/β-catenin-dependent proliferation. 
V. The expression of SOX17 is reduced in CCA human biopsies and cell 
lines compared to their controls. 
VI. Experimental overexpression of SOX17 in CCA human cells inhibits their 
tumorigenic capacity by increasing apoptosis and downregulating the 
Wnt/β-catenin proliferation and cell migration.  
VII. Experimental overexpression of SOX17 in CCA human cells increases 
the expression of biliary epithelial markers and restores the primary 
cilium length. 
VIII. The expression of SOX17 in normal human cholangiocytes is inhibited by 
the presence of TGFβ1 or Wnt3a via a DNA methylation mechanism. 
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IX. The basal expression of SOX17 is downregulated in CCA human cells 
via a DNMT1-dependent mechanism; experimental knocking-down of 
DNMT1 expression or the inhibition of its activity both restore SOX17 
expression in CCA human cells.  
  
 
  
 
  
  
 
 
 
 
 
 
 
 
VII. SUMMARY IN SPANISH 
(RESUMEN EN ESPAÑOL) 
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S.1. Antecedentes y objetivos 
El colangiocarcinoma (CCA) es un grupo heterogéneo de tumores 
caracterizados por la expresión de marcadores de diferenciación bilar. Su 
incidencia está aumentando en todo el mundo y representa ya el segundo tipo 
de tumor hepático más común después del carcinoma hepatocelular (HCC). El 
CCA es muy letal debido a su agresividad, diagnóstico tardío y elevada 
quimiorresistencia. A nivel molecular, el CCA está caracterizado por 
alteraciones genéticas y epigenéticas que determinan su patogénesis. 
Recientemente se ha descubierto que el genoma de los tumores de CCA se 
encuentra globalmente hipermetilado. En este sentido, se ha indicado que el 
promotor de SOX17 se encuentra entre dichos genes hipermetilados. SOX17 
parece ser un factor de transcripción clave en la embriogénesis biliar ya que 
ratones deficientes de SOX17 (SOX17-/-) presentan letalidad prematura debido 
a alteraciones biliares. Por ello, en este proyecto de investigación estudiamos 
el papel de SOX17 en la diferenciación y mantenimiento del fenotipo de los 
colangiocitos así como su relevancia en el proceso de colangiocarcinogénesis. 
 
S.2. Métodos 
Se evaluó la expresión y función de SOX17 durante la diferenciación de las 
células madre humanas pluripotentes inducidas (iPSCs) a colangiocitos, en la 
desdiferenciación de colangiocitos humanos normales (NHC) y en el CCA. Para 
ello se utilizaron lentivirus que sobreexpresan o inhiben SOX17 (Lent-SOX17 y 
Lent-shRNA-SOX17, respectivamente). Se realizaron ensayos de 
tumorigénesis en ratones inmunodeficientes y se analizó la apoptosis, 
proliferación, migración, estrés oxidativo, y fenotipo de las células tumorales en 
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ausencia o presencia de SOX17. Además, se realizaron estudios de expresión 
génica mediante microarrays. 
 
S.3. Resultados  
La expression de SOX17 está altamente inducida en la última etapa de la 
diferenciación iPSCs a colangiocitos, en particular en la fase de célula hepática 
progenitora a colangiocito diferenciado; además, SOX17 promueve en dicha 
fase la expresión de los marcadores biliares (CK) 7 y 19. Por otro lado,  SOX17 
también promueve el mantenimiento del fenotipo biliar en NHC a través de la 
expresión de CK7 y CK19, y sin afectar a la senescencia celular. La inhibición 
de la expresión de SOX17 mediante Lent-shRNA-SOX17 promueve la 
proliferación celular dependiente de la ruta Wnt/β-catenin. La expression de 
SOX17 se encuentra disminuida en células de CCA humano en cultivo (y 
biopsias tumorales humanas) en comparación con NHC o tejido de la vesícula 
biliar humana. En el modelo de tumorogénesis en ratones inmunodeficientes,  
en la inyección subcutánea de células de CCA humano (que sobreexpresaran o 
no SOX17) la sobreexpresión de SOX17 disminuye su capacidad tumorigénica 
en comparación con sus controles.  Dicho fenómeno es mediado a nivel 
molecular por el efecto de SOX17 aumentando el estrés oxidativo y la 
apoptosis en las células de CCA, así como inhibiendo su proliferación 
dependiente de la ruta Wnt/β-catenin y la migración celular. Curiosamente, la 
sobreexpresión de SOX17 en NHC no afecta a su supervivencia. Por otra 
parte, la sobreexpresión de SOX17 provoca una sobreexpresión de 
marcadores biliares epiteliares en las células de CCA humano, así como la 
restauración de la longitud del cilio primario. Tanto Wnt3a como TGFβ1 
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disminuyen la expresión de SOX17 en NHC de manera dependiente de 
metilación del DNA. La inhibición de la DNMT1 en las células de CCA humano 
con siRNAs o fármacos induce el aumento de los niveles de expresión de 
SOX17. 
 
S.4. Conclusión 
SOX17 regula la diferenciación y el mantenimiento del fenotipo biliar y su 
expression se encuentra epigenéticamente inhibida en el CCA. SOX17 actúa 
como supresor tumoral en el CCA, y la restauración de sus níveles de 
expresión puede tener un importante valor terapéutico. 
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